



A cohort study comparing cardiovascular risk factors in rural Māori, urban Māori and non-Māori communities in New Zealand

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000799
Article Type:	Research
Date Submitted by the Author:	04-Jan-2012
Complete List of Authors:	Cameron, Vicky; University of Otago, Christchurch, Christchurch Cardioendocrine Research Group Faatoese, Allamanda; University of Otago, Christchurch, Christchurch Cardioendocrine Research Group Gillies, Matea; University of Otago, Christchurch, Māori Indigenous Health Institute Robertson, Paul; University of Otago, Christchurch, Māori Indigenous Health Institute Huria, Tania; University of Otago, Christchurch, Māori Indigenous Health Institute Doughty, Rob; University of Auckland, Department of Medicine Whalley, Gillian; Unitec, Faculty of Social and Health Sciences Richards, Mark; University of Otago, Christchurch, Christchurch Cardioendocrine Research Group Troughton, Richard; University of Otago, Christchurch, Christchurch Cardioendocrine Research Group Tikao-Mason, Karen; University of Otago, Christchurch, Māori Indigenous Health Institute Wells, Elisabeth; University of Otago, Christchurch, Department of Public Health Sheerin, Ian; University of Otago, Christchurch, Department of Public Health Pitama, Suzanne; University of Otago, Christchurch, Māori Indigenous Health Institute
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Cardiovascular risk factors, Indigenous Health, Rural Health

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

A cohort study comparing cardiovascular risk factors in rural Māori, urban Māori and non-Māori communities in New Zealand.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Corresponding Author:

Associate Professor Vicky A Cameron, University of Otago, Christchurch,

PO Box 4345, Christchurch 8140, New Zealand

Phone: +64 3 364 1210 FAX: +64 3 364 0525 Email: Vicky.cameron@otago.ac.nz

Vicky A Cameron¹, Allamanda F Faatoese¹, Matea W Gillies², Paul J Robertson², Tania M Huria², Rob N Doughty³, Gillian A Whalley⁵, A Mark Richards¹, Richard W Troughton¹, Karen N Tikao-Mason², J Elisabeth Wells⁴, Ian G Sheerin⁴, Suzanne G Pitama²

¹ Christchurch Cardioendocrine Research Group, University of Otago, Christchurch 8140, New Zealand;

² Māori Indigenous Health Institute University of Otago, Christchurch 8140, New Zealand

⁴ Department of Public Health, University of Otago, Christchurch 8140, New Zealand

³ Department of Medicine, University of Auckland 1142, New Zealand,

⁵ Faculty of Social and Health Sciences, Unitec, Auckland 1025, New Zealand

Short Title **Cardiovascular risk in rural and urban Māori**

Key Words Indigenous Health; Cardiovascular Diseases; Risk Factors

ABSTRACT

Objectives: To understand health disparities in cardiovascular disease (CVD) in the indigenous Māori of New Zealand, diagnosed and undiagnosed CVD risk factors were compared in rural Māori in an area remote from health services with urban Māori and non-Māori in a city well served with health services.

Design: Prospective cohort study.

Setting: Hauora Manawa is a cohort study of diagnosed and previously undiagnosed CVD, diabetes, and risk factors, based on random selection from electoral rolls of the rural Wairoa District, New Zealand and Christchurch City, New Zealand.

Participants: Screening clinics were attended by 252 rural Māori, 243 urban Māori and 256 urban non-Māori, aged 20 – 64 years.

Main Outcome Measures: The study documented personal and family medical history, blood pressure, anthropometrics, fasting lipids, insulin, glucose, HbA1c, and urate.

Results: Mean age (SD) was 45.7 (11.5) vs 42.6 (11.2) vs 43.6 (11.5) years in rural Māori, urban Māori and non-Māori respectively. Age-adjusted rates of diagnosed cardiac disease were not significantly different across the cohorts (7.5% vs 5.8% vs 2.8%, $P=0.073$). However, rural Māori had significantly higher levels of type-2 diabetes (10.7% vs 3.7% vs 2.4%, $P<0.001$), diagnosed hypertension (25.0% vs 14.9% vs 10.7%, $P<0.001$), treated dyslipidaemia (15.7% vs 7.1% vs 2.8%, $P<0.001$), current smoking (42.8% vs 30.5% vs 15.2%, $P<0.001$) and age-adjusted BMI (30.7 (7.3) vs 29.1 (6.4) vs 26.1±6.4 vs 26.1 (4.5) kg/m², $P<0.001$). Similarly high rates of previously undocumented elevated blood pressure (22.2% vs 23.5% vs 17.6%, $P=0.235$) and high cholesterol (42.1% vs 54.3% vs 42.2%, $P=0.008$) were observed across all cohorts.

Conclusions: Supporting rural general practices to provide intensive screening and management of CVD risk factors would reduce health disparities in the New Zealand indigenous population.

ARTICLE SUMMARY

Article Focus

- The indigenous Māori of New Zealand have high rates of cardiovascular disease (CVD) mortality and morbidity. Current data on the key risk factors underlying this ethnic disparity mostly come from national surveys relying on self-reported diagnoses, or have been collected in New Zealand's largest urban centre, Auckland City.
- This is the first study to screen CVD and associated risk factors concurrently between rural Māori residing in an area remote from health services (Wairoa District), urban Māori in a city well served with secondary and tertiary health services (Christchurch City) and an urban non-Māori cohort.

Key Messages

- We found rural Māori had higher levels of obesity, smoking, hypertension, dyslipidaemia, DM2 and hyperuricaemia than either urban Māori or non-Māori. Thus national health surveys and data collected in large urban centres may significantly underestimate the burden of CVD risk carried by rural Māori.
- Public health initiatives to reduce rates of smoking among rural Māori, along with enhanced implementation of CVD screening in primary care and more intensive clinical management of hypertension, dyslipidaemia and hyperuricaemia would help reduce cardiovascular health disparities in the New Zealand indigenous population.

Strengths and Limitations of the Study

- This study was able to determine current levels of both diagnosed and undiagnosed risk factors within these communities by conducting CVD screening clinics in sectors of the community that are often hard-to-reach. The findings of this study are limited by the relatively small cohort sizes and lack of a rural non-Māori comparator cohort.

INTRODUCTION

The indigenous Māori, comprising approximately 15% of the New Zealand (NZ) population, have high rates of cardiovascular disease (CVD) mortality and morbidity^{1,2}. For the period 1996–1999 CVD mortality among Māori males was 3.0 times higher than that for non-Māori, non-Pacific males and Māori female mortality rates were 4.2 times higher than that for non-Māori, non-Pacific females². Key risk factors underlying the ethnic disparity in CVD have recently been reported in Auckland City, New Zealand's largest urban centre (population approx 1.5 million), using data from general practice clinical databases³ and from community studies⁴⁻⁸. However, three quarters of Māori live outside of Auckland⁹ and nearly 16 percent reside in rural areas. Recent health statistics indicate that ischaemic heart disease rates are higher among those living in rural areas than in urban New Zealanders¹⁰. Furthermore, rural Māori have a shorter life expectancy than urban Māori, with 1.5 years difference for men and 1.2 years difference for women¹⁰, greater than the urban-rural difference in the general population of 0.8 and 0 years for men and women respectively. Life expectancy for rural Māori is less than the overall rural population by 7.2 years for men and 6.6 years for women¹⁰. We have recently reported high levels of both diagnosed and undiagnosed CVD risk factors, especially hypertension, dyslipidaemia and diabetes in a rural Māori community¹¹, with several major risk factors at higher levels than those reported than either national statistics or for Auckland City Māori. To understand how CVD risk factors differ between diverse localities across New Zealand, we have compared the cardiovascular risk profiles of two regionally distinct, rural and urban Māori communities and a matched, urban comparator cohort of non-Māori. This is the first study to screen CVD and associated risk factors concurrently in rural Māori residing in an area remote from health services and in urban Māori in a metropolitan area well served with secondary and tertiary health services.

METHODS

Localities

The Hauora Manawa/ Community Heart Study is a cohort study of heart disease in NZ, based on random selection from electoral rolls, sampled to be representative of the age and gender profiles within each participating Māori community. The Wairoa District is located in rural Hawkes Bay on the North Island of NZ with a population in 2006 of 8481 of whom 61% identified as Māori ethnicity. It is located two hours north by road of the nearest, fully serviced hospital. Christchurch is the largest city in the South Island with a population in 2006 of 348,435, of whom 7.6% identified as Māori, and 75.4% identified as New Zealand European. Christchurch has a large (600-650 bed) tertiary, teaching and research hospital that provides a full range of emergency, acute, elective and outpatient services.

Participants

Full details of kaupapa Māori methodology, sample selection, recruitment and interviewing processes are published elsewhere¹². In brief, participants, aged between 20 to 64 years, stratified by age and sex, were randomly selected from the electoral roll for Wairoa District and for Christchurch City (excluding Banks Peninsula Ward, a largely rural area amalgamated with Christchurch City in 2006). Participants for the Māori samples were selected from among those who identified as being of Māori descent on the roll and who self-identified at interview as being of Māori ethnicity. The Christchurch non-Māori descent selection was frequency matched to the sex- and age-group distribution of the Christchurch Māori descent sample. The overall response rates were 57.6% (95% CI 53.0, 62.2; 254/441) for the Wairoa Māori descent sample, 48.3% (95% CI 44.1, 52.4; 267/553) for the Christchurch Māori descent sample, and 57.2% (95% CI 52.7, 61.8; 257/449; 254/340) for the Christchurch Non-Māori descent sample. The cooperation rates rate (participation among those with whom contact was established) were 74.7% (95% CI 70.1, 79.3) for the Wairoa Māori, 66.6% (95%

1
2 CI 62.0, 71.2; 267/401) for the Christchurch Māori, and 71.4% (95%CI 66.7, 76.1; 257/360)
3
4 for the Christchurch Non-Māori group. The study was approved by the Multi-Region Ethics
5
6 Committee (Reference MEC/06/03026) and all participants provided written, informed
7
8 consent.
9

10 11 12 13 **Screening clinics**

14
15 Screening clinics were held at Wairoa Hospital (May to December 2007) or at the
16
17 Māori/Indigenous Health Institute (MIHI), Christchurch, (January to December 2008), as
18
19 described previously¹¹. In brief, all participants completed an interviewer-administered
20
21 questionnaire providing demographic, personal and family medical history, current
22
23 medications, smoking status recorded as current, ex-smoker (quit more than 12 months) or
24
25 never smoker, alcohol consumption, physical activity levels (physically active defined as “at
26
27 least 30 minutes of moderate or vigorous physical activity on 5 or more days of the week”)
28
29 and socioeconomic data. Blood pressure was recorded (two measurements, seated, at least 20
30
31 minutes apart), height, weight, waist and hip measurements were taken and body mass index
32
33 (BMI) calculated. Body composition analysis was performed by bioimpedance using the
34
35 Tanita Body Composition Analyser, TBF 310 (Tanita Inc, Tokyo, Japan), and the output
36
37 automatically classified participants in the healthy body fat, overweight body fat and obese
38
39 body fat ranges according to age and gender. Fasting blood samples were collected and
40
41 assayed for full blood differential cell counts, plasma lipid profiles, glucose, insulin,
42
43 creatinine, homocysteine, HbA1c and urate (Wairoa Hospital Laboratory, Hawkes Bay
44
45 District Health Board or Canterbury Health Laboratories, Christchurch Hospital).
46
47
48
49
50

51
52
53 A prior cardiac history was defined as a history of diagnosed myocardial infarction, angina,
54
55 heart failure, coronary artery bypass graft (CABG) surgery, percutaneous transluminal
56
57 coronary angioplasty (PTCA), pacemaker, other cardiac intervention or ischaemic stroke.
58
59
60

1
2 Confirmation of prior diagnoses and current management of CVD risk factors were obtained
3
4 from primary care physicians for all participants. A new diagnosis of hypertension and
5
6 dyslipidaemia was made at screening in those with levels above the reference ranges with no
7
8 prior diagnosis and who were not receiving treatment. Hypertension was documented if the
9
10 average of the two blood pressure readings gave a SBP >140mmHg or DBP >90mmHg.
11
12 Dyslipidaemia was diagnosed if the total cholesterol:HDL-cholesterol (TC:HDL) ratio was
13
14 >4.0. The Bestpractice[©] electronic decision support software (Bestpractice[©], 2005 – 2009,
15
16 Dunedin, NZ) was also used to classify participants with metabolic syndrome at screening.
17
18
19
20
21

22 **Statistical analysis**

23
24 All statistical analyses were performed using SPSS v13.0 (Chicago, Illinois, USA). Data are
25
26 expressed as mean (SD) or as percentages. Data collection was complete except for
27
28 anthropometric data for one rural participant. Logistic regression analyses were used to
29
30 compare binary outcomes across the three cohorts and univariate analysis for continuous
31
32 variables, and both unadjusted *P* values and *P* values corrected for age and gender are
33
34 presented. Pairwise comparisons (rural versus urban Māori; urban Māori vs urban non-Māori)
35
36 were carried out using analysis of variance or chi-square tests, as appropriate for continuous
37
38 or discrete variables respectively. For discrete non-binary variables, overall chi-square on a 3
39
40 X 3 table were used followed by a separate 2 X 3 chi-square test for each pairwise
41
42 comparison. Significance levels were set as $P \leq 0.05$.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Baseline characteristics and prior diagnoses

The baseline characteristics of the 751 participants who attended the screening clinics are shown in Table 1. Rural Māori participants, at a mean age of 45.7 years, were older than both urban cohorts (42.6 years and 43.6 years). Comparisons of key risk factors contributing to CVD risk across the three cohorts are described below.

Rates of prior cardiac history showed a non-significant trend to be higher in Māori than non-Māori ($P=0.073$, Table 1). Although age of onset of CVD tended to be lower in urban Māori than either of the other groups, the differences among the three cohorts were not significant (51.8 ± 9.8 vs 43.8 ± 5.7 vs 50.2 ± 8.2 years, $P=0.539$, for rural Māori, urban Māori and urban non-Māori respectively). A prior diagnosis of rheumatic fever had been made in 2% of Wairoa cohort, 0% of urban Māori and 0.4% of urban non-Māori. Of those with a personal cardiac history, 68% of rural Māori, 100% urban Māori and 71% non-Māori reported having first-degree family history of CVD. Overall, including those both with and without a personal cardiac history, the rates of first-degree family history of CVD were 52% rural Māori vs 58% urban Māori vs 55% non-Māori ($P=0.401$).

A prior diagnosis of hypertension was more common in rural Māori than urban non-Māori (Table 1), but not significantly different between the two urban groups, and this was reflected in higher rates of treatment with antihypertensive medications in rural Māori (21.4 vs 11.9 vs 8.6 %, $P<0.001$). Mean systolic (SBP) and diastolic blood pressure (DBP) levels at screening were slightly, but significantly higher in both Māori groups compared to non-Māori.

Table 1. Baseline Characteristics and Cardiovascular Risk Factors in Rural Māori, Urban Māori and Urban Non-Māori

	Rural Māori (N=252) (a)	Urban Māori (N=243) (b)	Non-Māori (N=256) (c)	Overall Unadj <i>P</i> (Adj <i>P</i>)	(a) vs (b) Unadj <i>P</i> (Adj <i>P</i>)	(b) vs (c) Unadj <i>P</i> (Adj <i>P</i>)	(a) vs (c) Unadj <i>P</i> (Adj <i>P</i>)
Age	45.7 (11.5)	42.6 (11.2)	43.6 (11.5)	0.009	0.003	0.339	0.038
Gender, % Female (n)	59.5 (150)	54.7 (133)	51.2 (131)	0.166	0.282	0.426	0.059
Cardiac History*, % (n)	7.5 (19)	5.8 (14)	2.8 (7)	0.066 (0.073)	0.443 (0.942)	0.101 (0.038)	0.020 (0.034)
Hypertension, % (n)	25.0 (63)	14.9 (36)	10.7 (27)	<0.001 (0.001)	0.006 (0.115)	0.157 (0.061)	<0.001 (<0.001)
Systolic Blood Pressure, mmHg, mean (SD)	130.8 (18.5)	128.2 (20.6)	124.5 (14.8)	<0.001 (<0.001)	0.112 (0.074)	0.021 (0.010)	<0.001 (<0.001)
Diastolic Blood Pressure, mmHg, mean (SD)	85.3 (11.1)	86.2 (13.6)	83.0 (12.1)	0.011 (0.002)	0.391 (0.358)	0.004 (0.002)	0.039 (0.028)
Treated Dyslipidaemia, % (n)	15.7 (39)	7.1 (17)	2.8 (7)	<0.001 (<0.001)	0.004 (0.051)	0.032 (0.007)	<0.001 (<0.001)
Total Cholesterol (TC), mmol/L, mean (SD)	5.1 (1.1)	5.2 (1.0)	5.3 (1.1)	0.057 (0.032)	0.112 (0.101)	0.438 (0.423)	0.018 (0.015)

LDL-cholesterol, mmol/L, mean (SD)	3.2 (0.9)	3.3 (0.8)	3.4 (0.9)	0.017 (0.009)	0.042 (0.036)	0.462 (0.449)	0.006 (0.004)
HDL-cholesterol, mmol/L, mean (SD)	1.2 (0.3)	1.2 (0.3)	1.3 (0.3)	<0.001 (<0.001)	0.645 (0.629)	<0.001 (<0.001)	<0.001 (<0.001)
Triglycerides, mmol/L, mean (SD)	1.5 (0.8)	1.4 (1.1)	1.2 (0.7)	0.003 (<0.001)	0.491 (0.474)	0.009 (0.007)	0.001 (0.001)
TC:HDL ratio, mean (SD)	4.2 (1.1)	4.3 (1.1)	4.1 (1.3)	0.221 (0.088)	0.329 (0.305)	0.083 (0.069)	0.484 (0.462)
Urate, mmol/L, mean (SD)	0.338 (0.897)	0.300 (0.093)	0.276 (0.085)	<0.001 (<0.001)	<0.001 (<0.001)	0.003 (0.001)	<0.001 (<0.001)

Continuous variables expressed as means (SD). Adj $P = P$ value adjusted for age and gender.

* Defined as a history of myocardial infarction, angina, heart failure, coronary artery bypass graft (CABG) surgery, percutaneous transluminal coronary angioplasty (PTCA), pacemaker, other cardiac intervention or ischaemic stroke

1
2
3 Rates of previously diagnosed, treated dyslipidaemia were highest in rural Māori, followed by
4
5 urban Māori and lowest in non-Māori (Table 1, $P<0.0001$). However, mean values of the key
6
7 cholesterol variables were above the recommended ranges set by national cardiovascular
8
9 guidelines in all three cohorts ¹³, with urban Māori tending to have the least favourable lipid
10
11 profiles. Urban Māori had higher LDL cholesterol levels than rural Māori although mean
12
13 levels of TC, HDL-cholesterol, triglycerides and TC: HDL ratios did not differ between the
14
15 two Māori communities. Urban Māori also had higher triglycerides and lower HDL
16
17 cholesterol levels compared to non-Māori, while mean levels of TC, LDL-cholesterol and TC:
18
19 HDL ratios were similar between the two urban cohorts.
20
21
22
23
24

25 Plasma urate has been reported to be an independent risk factor for CVD ¹⁴. Plasma urate
26
27 levels were significantly higher in rural Māori than urban Māori, which were also higher than
28
29 in non-Māori (Table 1). Urate levels were above the reference ranges (0.42mmol/L in males
30
31 and 0.37mmol/L in females) in 25% of rural Māori, 10% of urban Māori and 5% non-Māori.
32
33 Previously diagnosed gout was reported by 6% of rural and 4% of urban Māori and 0.4% non-
34
35 Māori. Of those, 56% of rural Māori, 22% urban Māori and 0% non-Māori had plasma urate
36
37 levels above the gender-specific thresholds at screening.
38
39
40
41
42

43 **Metabolic risk factors**

44
45 A prior diagnosis of DM2 (Table 2) was significantly more frequent in rural Māori compared
46
47 to either urban Māori or non-Māori cohorts. In DM2 patients, 48.1% of rural Māori, 66.7%
48
49 urban Māori and 33.3% non-Māori with DM2 had a first-degree family history of DM2.
50
51 Overall, including those with and without DM2, rates of first-degree family history of DM2
52
53 were 43% vs 31% vs 21% non-Māori ($P<0.001$). Metabolic syndrome, diagnosed at
54
55
56
57
58
59
60

1
2
3 screening, was significantly more prevalent in both rural and urban Māori than non-Māori
4
5 (Table 2).
6
7

8
9 A gradient in BMI was seen across the three cohorts (Table 2), with both the age-adjusted
10 mean BMI and the proportion with a BMI in the obese range being greatest in rural Māori and
11 lowest in non-Māori. A similar gradient was observed in percent body fat, with more rural
12 Māori classified in the combined overweight and obese percent body fat categories and more
13 urban Māori than non-Māori in these categories ($P<0.001$). In contrast, there was a
14 significantly higher mean fat-free mass in both Māori communities compared to non-Māori.
15
16 The waist to hip ratios were slightly higher in rural Māori than either of the two urban groups
17 ($P=0.005$ to $P<0.001$). The mean levels of the diabetes risk markers (fasting glucose, HbA1c
18 and fasting insulin) were significantly higher in rural Māori than urban Māori, remaining
19 significant after adjusting for gender and age ($P<0.001$), with HbA1c and insulin also higher
20 in urban Māori than non-Māori. Inclusion of BMI into the univariate model accounted for
21 cohort differences in fasting insulin levels and fasting glucose. However, HbA1c levels, even
22 when adjusted for age, gender and BMI, remained significantly higher in rural Māori than
23 urban Māori ($P<0.001$) and higher in urban Māori than non-Māori ($P<0.001$).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Diabetes, Anthropometrics, Smoking, Alcohol and Physical Activity in Rural Māori, Urban Māori and Urban Non-Māori

	Rural Māori	Urban Māori	Non-Māori	Overall	(a) vs (b)	(b) vs (c)	(a) vs (c)
	(N=252)	(N=243)	(N=256)	Unadj P	Unadj P	Unadj P	Unadj P
	(a)	(b)	(c)	(Adj P)	(Adj P)	(Adj P)	(Adj P)
Type 2 diabetes, % (n)	10.7 (27)	3.7 (9)	2.4 (6)	<0.001 (0.001)	0.004 (0.024)	0.382 (0.279)	0.001 (0.001)
Metabolic Syndrome, % (n)	35.9 (90)	27.1 (65)	14.5 (37)	<0.001 (<0.001)	0.037 (0.139)	0.001 (<0.001)	<0.001 (<0.001)
BMI, mean (SD)	30.7 (7.3)	29.1 (6.4)	26.1 (4.5)	<0.001 (<0.001)	0.004 (0.003)	<0.001 (<0.001)	<0.001 (<0.001)
BMI Categories:							
Healthy BMI % (n)	21.9 (55)	29.2 (71)	45.7 (117)	<0.001	0.079	<0.001	<0.001
Overweight % (n)	30.3 (76)	32.1 (78)	38.3 (98)				
Obese BMI % (n)	47.8 (120)	38.7 (94)	16.0 (41)				
Percent body fat %, mean (SD)	35.0 (10.7)	32.2 (9.4)	28.7 (9.0)	<0.001 (<0.001)	0.001 (<0.001)	<0.001 (<0.001)	<0.001 (<0.001)
Percent body fat categories:							
Healthy body fat % (n)	20.4 (50)	30.5 (73)	41.0 (105)	<0.001	0.066	<0.001	<0.001

Overweight body fat % (n)	25.7 (63)	23.4 (56)	31.6 (81)				
Obese body fat % (n)	51.4 (126)	44.8 (107)	25.0 (64)				
Fat Free Mass, kg, mean (SD)	55.2 (11.2)	55.8 (12.3)	53.8 (10.5)	0.114 (<0.001)	0.534 (0.285)	0.043 (0.001)	0.159 (0.016)
Waist:Hip Ratio, mean (SD)	0.91 (0.08)	0.90 (0.10)	0.89 (0.08)	0.012 (<0.001)	0.034 (0.005)	0.479 (0.351)	0.004 (<0.001)
Glucose, mmol/L, mean (SD)	5.7 (1.7)	5.4 (0.9)	5.3 (0.5)	<0.001 (<0.001)	0.003 (0.002)	0.203 (0.186)	<0.001 (<0.001)
HBA1c, %, mean (SD)	6.3 (1.2)	5.4 (0.7)	5.2 (0.4)	<0.001 (<0.001)	<0.001 (<0.001)	0.002 (0.001)	<0.001 (<0.001)
Insulin, pmol/L, mean (SD)	65.6 (56.9)	52.7 (54.5)	42.7 (34.4)	<0.001 (<0.001)	0.005 (0.005)	0.025 (0.024)	<0.001 (<0.001)
Smoking:							
Current % (n)	42.8 (108)	30.5 (74)	15.2 (39)	<0.001	<0.001	<0.001	<0.001
Ex-smoker % (n)	38.5 (97)	33.3 (81)	29.3 (75)				
Never smoked % (n)	19.0 (48)	36.2 (88)	55.5 (142)				
Cigarette pack years, mean (SD)	5737 (4910)	5469 (5429)	4308 (5760)	0.045 (0.058)	0.615 (0.588)	0.060 (0.042)	0.015 (0.009)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Alcohol Drinkers, % (n)	81.3 (205)	92.2 (224)	91.4 (234)	<0.001	0.001	0.753	0.001
				(0.002)	0.003	0.808	0.005
Physically Active % (n)	68.3 (172)	70.8 (172)	64.8 (166)	0.362	0.157	0.542	0.416
				(0.316)	(0.380)	(0.132)	(0.380)

Continuous variables expressed as means (SD). Adj *P* = *P* value adjusted for age and gender.

Ranges for BMI were healthy range, BMI ≥ 18.5 <25.0kg/m²; overweight, BMI 25.0 – 29.9 kg/m²; obese ≥ 30.0 kg/m². Healthy, overweight and obese body fat ranges calculated using Tanita Body Composition Analyser, TBF 310.

Lifestyle risk factors

Rural Māori had the highest rate of current smoking (Table 2). In both Māori cohorts more females were current smokers and more males were ex-smokers; however there was a trend for males to have a higher calculated number of pack years than females across all three cohorts. Current smokers were of similar mean age (42.0 ± 10.5 vs 41.0 ± 10.7 vs 40.7 ± 12.5 years, $P=0.754$).

Alcohol drinking was significantly less common in rural Māori than either urban Māori or non-Māori ($P=0.002$), but the two urban communities were similar in their proportions of alcohol drinkers. The mean age of current drinkers tended to be similar in all three cohorts (rural Māori 44.5 ± 11.4 vs urban Māori 42.4 ± 11.2 years; non-Māori 43.1 ± 11.4 years, $P=0.153$). Recommended sessional drinking limits (no more than 6 standard drinks per session) were reported to be exceeded daily by 2% rural Māori, 3% urban Māori, 1% non-Māori, weekly by 26% rural Māori, 21% urban Māori and 11% urban non-Māori, monthly or less by 55% rural Māori, 44% urban Māori and 48% non-Māori drinkers.

Physical activity within recommended guidelines was reported by similar proportions of rural Māori, urban Māori and non-Māori (Table 1). Physical activity was not independently associated with any other cardiovascular risk factors.

Almost all participants were registered with a General Practitioner (GP) at the time of screening. Similar proportions of each cohort had visited their doctor within the last 6 months (69% vs 61% vs 66%) or had visited their doctor within the last 12 months (85% vs 74% vs 79%).

Levels of previously undiagnosed hypertension and dyslipidaemia

At screening, approximately 20% of each community were found to have blood pressures above the recommended range (Undiagnosed Hypertension, Table 3). Overall, the combined rates of diagnosed and undiagnosed hypertension across the three cohorts were not significantly different between the two Māori cohorts when adjusted for age, but higher in urban Māori than in non-Māori.

For rural Māori, key risk factors in a logistic regression model for predicting hypertension were gender x age (OR=1.243 (1.061 - 1.155), $P<0.0001$), BMI (OR=1.107 (1.033 - 1.135), $P<0.001$), current smoker (OR=0.461 (0.213 - 0.995), $P=0.049$) and family history of hypertension (OR=2.042 (1.178 - 3.540), $P=0.011$). For urban Māori, key risk factors for predicting hypertension were gender x age (OR=1.257 (1.106 - 1.430), $P<0.0001$), an obese % body fat, (OR=4.394 (2.168 - 8.907), $P<0.0001$) and family history of hypertension (OR=1.972 (1.074 - 3.619), $P=0.029$). Among non-Māori, the interaction of gender x fasting triglyceride levels (OR=1.886 (1.366 - 2.603), $P<0.0001$) and age (OR=1.512 (1.161-1.968), $P=0.002$) were the risk factors significantly associated with having hypertension.

New diagnoses of dyslipidaemia made at screening (Undiagnosed Dyslipidaemia, Table 3) were significantly more common in urban Māori after accounting for age than in either rural Māori or non-Māori. Overall, when diagnosed and undiagnosed dyslipidaemia were combined, over half of each Māori cohort and 45% of non-Māori were dyslipidaemic.

For rural Māori, the only independent risk factor identified in a logistic regression model for predicting dyslipidaemia was waist circumference (OR=1.027 (1.009 - 1.044), $P=0.003$). In urban Māori, dyslipidaemia was predicted by an interaction of gender and BMI (OR=0.960

1
2
3 (0.94 – 0.98, $P<0.0001$, male being protective) and an inverse effect of first-degree family
4
5 history of high cholesterol (OR=0.55 (0.32 – 0.96), $P=0.034$). The interaction of gender x
6
7 BMI was also identified in urban non-Māori; associated with a protective effect in males
8
9 (OR=0.95 (0.93 – 0.97), $P<0.0001$).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Prior and New Diagnoses of Cardiovascular Risk Factors in Rural Māori, Urban Māori and Urban Non-Māori

	Rural Māori	Urban Māori	Non-Māori	Overall	(a) vs (b)	(b) vs (c)	(a) vs (c)
	(a)	(b)	(c)	Unadj <i>P</i>	Unadj <i>P</i>	Unadj <i>P</i>	Unadj <i>P</i>
				(Adj <i>P</i>)	(Adj <i>P</i>)	(Adj <i>P</i>)	(Adj <i>P</i>)
Hypertension:							
Prior Diagnosis Hypertension, %	25.0	14.8	10.5	<0.001	0.006	0.157	<0.001
				(0.001)	(0.115)	(0.061)	(<0.001)
Undiagnosed Hypertension, %	22.2	23.5	17.6	0.235	0.744	0.105	0.191
				(0.124)	(0.744)	(0.054)	(0.109)
Total hypertension, %	47.2	38.3	28.1	<0.001	0.045	0.016	<0.001
				(<0.001)	(0.236)	(0.002)	(<0.001)
Dyslipidaemia:							
Prior Diagnosis Dyslipidaemia, %	15.7	7.1	2.8	<0.001	0.004	0.032	<0.001
				(<0.001)	(0.051)	(0.007)	(<0.001)
Undiagnosed Dyslipidaemia, %	42.6	55.0	42.4	0.008	0.005	0.006	0.961
				(0.004)	(0.014)	(0.002)	(0.570)
Total Dyslipidaemia, %	58.2	62.2	45.6	0.001	0.373	<0.001	0.005
				(<0.001)	(0.261)	(<0.001)	(<0.001)

Undiagnosed = no prior diagnoses or receiving treatment; Total diagnoses = Potential + Previous diagnosis; Adj *P*-value = adjusted for age

DISCUSSION

Cardiovascular disease is the major factor contributing to the ethnic disparities of life expectancy between Māori and non-Māori in NZ, and yet how key risk factors contributing to this discrepancy vary across different localities has not previously been described. To our knowledge, this is the first study to compare current levels of CVD and associated risk factors between two regionally distinct Māori communities; rural Māori residing in an area remote from health services and urban Māori in a city well served with secondary and tertiary health services, as well as non-Māori residing in the same locality. The salient finding was a gradient of cardiovascular risk with the highest burden of CVD risk in rural Māori, particularly obesity, smoking, hypertension, dyslipidaemia, DM2 and hyperuricaemia. Increased measures of body mass were key risk factors associated with the elevated fasting insulin and glucose levels, diagnosed hypertension and dyslipidaemia in both Māori cohorts, but particularly in rural Māori. However, we also observed that undiagnosed hypertension and dyslipidaemia were common across all three New Zealand population groups, despite the establishment of nationwide CVD screening guidelines.

Findings in relation to national statistics

The 2006/07 New Zealand Health Survey documented self-reported health information across the New Zealand population, and included analysis by ethnicity but not by locality¹⁵.

National prevalence rates were comparable to levels of CVD risk factors we observed in urban Māori but would substantially underestimate CVD risk in rural Māori. For example, 13.6% of the national population reported having medicated high blood pressure¹⁵, similar to the 14.9% in our urban Māori but less than the 25% in our rural Māori participants.

Nationwide, one in twelve adults (8.4%) had medicated high cholesterol, comparable to the 7.1% in urban Māori in the current study but less than the 15.7% in rural Māori. The national

1
2
3 prevalence of diagnosed DM2 was 5% in the general population ¹⁵ and 5.8% in Māori (age-
4
5 adjusted) ¹⁵. Rural Māori in the current study had double those rates (10.7%) compared to
6
7 only 3.7% in urban Māori and 2.4% in non-Māori. National rates of smoking remain higher
8
9 in Māori (42.2%) compared to the general New Zealand population (19.9%) ¹⁵. In the current
10
11 study, 42.8% of rural Māori and 30.5% of urban Māori were smokers compared to 15% of
12
13 urban non-Māori. In the New Zealand Health Survey only 50.5% of adults report being
14
15 physically active ¹⁵. In the current study, around 70% of each cohort reported being physically
16
17 active, consistent with national data reporting that Māori are at least as physically active as
18
19 any other ethnic group in New Zealand ¹⁵. It is apparent that the large BMIs and metabolic
20
21 risk factors observed among the Māori participants were not associated with a less active
22
23 lifestyle.
24
25
26
27
28

29 Plasma urate levels, an independent predictor of cardiovascular disease ¹⁴, were above
30
31 reference ranges in 25% of rural Māori and 10% of urban Māori. The national prevalence of
32
33 gout is 1.3%, substantially lower than in the current study, with 6% of rural Māori and 4% of
34
35 urban Māori having been diagnosed by a doctor with gout. It has been known for some
36
37 decades that gout is a common problem in Māori and Pacific Islanders ¹⁶⁻¹⁸ as a result of a
38
39 difference in renal urate handling ¹⁹. Very recently, two genetic variants have been shown to
40
41 have genome-wide significant association with gout ²⁰. One of these, a variant form of the
42
43 renal urate transporter gene, SLC2A9, has been shown to be significantly associated with gout
44
45 in Māori and Pacific Island patients ²¹. Serum urate levels may be an important underlying
46
47 risk factor in Māori and Pacific people.
48
49
50
51
52
53

54 **Findings in relation to other regional studies**

55
56
57
58
59
60

1
2
3 The current community cohort design is comparable with an Auckland study based on cross-
4 sectional sampling, the Diabetes Heart and Health Survey 2002/2003 ⁴⁻⁶. In that study, 37% of
5 Māori and 22% of others had raised blood pressure, with 7% of Māori and 2% of others
6 having previously undetected high blood pressure; more diagnosed but less undiagnosed
7 hypertension than in the current study. Mean total: HDL cholesterol ratios were 4.32 in Māori
8 and 4.04 in others, comparable to our urban Māori and non-Māori cohorts. In addition,
9 approximately 94% of participants had total cholesterol levels above 4.0 mmol/L, similar to
10 the current study (90.7% across all three cohorts); an alarming proportion of each cohort with
11 lipid profiles above recommended ranges. These findings suggest that elevated cholesterol is
12 a key risk factor that is widespread in the New Zealand population and could be more
13 intensively screened and managed throughout primary care. The Auckland prevalence of
14 DM2 was 12% in Māori ⁸, similar rates to the rural Māori, and 3.9% in Europeans similar to
15 both our urban cohorts. Metabolic syndrome was identified in 32% Auckland Māori and 16%
16 of others ⁶. This was less than in our rural Māori sample (35.9%) but similar to our urban
17 cohorts (27.1% and 14.5%). In combination, these data suggest that levels of several risk
18 factors in rural Wairoa Māori exceed those among Māori living in Auckland, especially
19 smoking, undiagnosed hypertension and metabolic syndrome. This contrasts with prior
20 studies from Thailand ²² and Peru ²³, that reported higher metabolic and CVD risk factors in
21 urban dwellers than rural residents. However, in Australia metabolic risk was higher in rural
22 patients with DM2 ²⁴, as in the current study.

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49 The current findings reflect a previous study of metabolic and cardiovascular health in a rural
50 Māori community of the Tuhoe tribe performed fifty years ago ^{25,26}. Prior et al screened 212
51 Tuhoe adults living in the isolated Ruatahuna Valley in the Urewera region ^{25,26}. The study
52 highlighted high rates of coronary heart disease, obesity, high cholesterol, hyperuricaemia,
53
54
55
56
57
58
59
60

1
2
3 clinical gout and diabetes. It is difficult to compare the specific data with the current study, as
4
5 many of the indices measured are no longer in use, such as “relative weight” and the use of
6
7 skin fold measurements to assess body fat. There was a 5% prevalence of rheumatic heart
8
9 disease; considerably higher than the 2% of rural Māori in the current study. Rates of smoking
10
11 were 59% among men and 70% among women, also substantially higher than we observed in
12
13 the rural Wairoa cohort. However, mean blood pressure and rates of DM2 were similar to
14
15 current Wairoa residents. From those findings, alongside the current study, it would appear
16
17 that health issues besetting rural Māori have improved only a little over the past half century.
18
19

20 21 22 23 **Strengths and limitations of the study**

24
25 This study was able to determine current levels of both diagnosed and undiagnosed risk
26
27 factors within these communities by conducting CVD screening clinics in sectors of the
28
29 community that are often hard-to-reach. Prior reports based on areal surveys (usually reliant
30
31 on self-reported diagnoses) or clinical databases may substantially underestimate disease rates
32
33 and risk factors in indigenous population groups who may not have equivalent access to
34
35 health care or CVD screening. The findings of this study are limited by the relatively small
36
37 cohort sizes and lack of a rural non-Māori comparator cohort, the study design being
38
39 constrained by the costs of the in-depth CVD screening.
40
41
42
43
44

45 In conclusion, this study reports that compared to either urban Māori or non-Māori, there is a
46
47 greater burden of CVD risk factors, particularly obesity, hypertension, dyslipidaemia, DM2,
48
49 hyperuricaemia and smoking in rural Māori, who have remained largely unstudied for the past
50
51 half-century. Moreover, the findings demonstrate that CVD risk profiles ascertained in
52
53 national health surveys or in New Zealand’s largest metropolitan population do not
54
55 necessarily reflect other localities; Christchurch Māori appear to have lower risk than
56
57
58
59
60

1
2
3 Auckland Māori, while Māori living in rural Wairoa have substantially higher risk. Despite
4
5 two-thirds of all three cohorts reporting visiting their primary care physicians in the past six to
6
7 twelve months, the study identified similarly high levels of undiagnosed hypertension and
8
9 elevated cholesterol in each of the population samples. Rural Māori participants reported
10
11 similar attendance of participants with their GPs, indicating good engagement with primary
12
13 care and suggesting that higher rates of some risk factors among the rural contingent were not
14
15 necessarily associated with barriers to accessing primary care. However, it seems likely public
16
17 health initiatives to reduce rates of smoking among Māori, along with enhanced
18
19 implementation of CVD screening in primary care and more support for rural general
20
21 practices to provide intensive clinical management of hypertension, dyslipidaemia and
22
23 hyperuricaemia would help reduce the CVD health disparities in the New Zealand indigenous
24
25 population.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGEMENTS:

We express our thanks to the Wairoa Community (Participants and their whanau, Wairoa Taiwhenua, The General Practice Surgeries and Māori Health Providers), the Christchurch Community (Participants and their whanau, Mana whenua ki Waitaha, Pegasus Health and Christchurch Primary Health Care Organisations), and the Māori Advisory Group for the Hauora Manawa project. We are grateful to Professor Gary Nicholls, Dr John Irvine, Dr Cameron Lacey and Wendy Dallas-Katoa for clinical assistance.

COMPETING INTERESTS:

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

CONTRIBUTORS:

VAC and SGP were responsible for the concept and study design, grant writing, supervising recruitment and screening clinics and VAC drafted the manuscript. They are the guarantors. EJW was responsible for overall statistical design, random selection process and contributed to data interpretation. AFF assisted at screening clinics, performed statistical analysis and assisted in drafting the manuscript. MWG, PJR, TMH, RND, GAW, AMR and RWT provided clinical expertise for CVD screening, performed echocardiography (not reported here), interpretation of clinical data and management of referrals for risk factors. KNT-K coordinated the study, especially communication with participants. IGS was involved in study design and edited drafts of the manuscript. All authors had full access to all of the data

1
2
3 (including statistical reports and tables) in the study and can take responsibility for the
4
5 integrity of the data and the accuracy of the data analysis.
6

7 **DATA SHARING:**
8

9 There is no additional data available.
10

11 **FUNDING:**
12

13
14 This work was supported by project grants from the Health Research Council of NZ (Grant
15
16 06/389) and the Heart Foundation of NZ (Project Grant 1273). Additional support was
17
18 provided by PHARMAC, Hawkes Bay District Health Board, Canterbury District Health
19
20 Board, Bestpractice[©] electronic decision support software and Hubbards Cereals (breakfast for
21
22 fasting participants at screening clinics).
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Ajwani S, Blakely T, Robson B, et al. Decades of Disparity: Ethnic mortality trends in New Zealand 1980 -1999. Public Health Intelligence 2003; Occasional Bulletin Number 16. Wellington: Ministry of Health and University of Otago; 2003.
2. Bramley D, Riddell T, Crengle S, et al. A call to action on Maori cardiovascular health. *NZMJ* 2004;**117**(1197) URL: <http://www.nzma.org.nz/journal/117-1197/957/>
3. Riddell T, Jackson R, Wells S, et al. Assessing Maori/non-Maori differences in cardiovascular disease risk and risk management in routine primary care practice using web-based clinical decision support: (PREDICT CVD-2). *NZMJ* 2007;**120**(1250) URL: <http://www.nzma.org.nz/journal/120-1250/2445/>
4. Gentles D, Metcalf P, Dyal L, et al. Blood pressure prevalences and levels for a multicultural population in Auckland, New Zealand: results from the Diabetes, Heart and Health Survey 2002/2003. *NZMJ* 2006;**119**(1245) URL: <http://www.nzma.org.nz/journal/119-1245/2318/>
5. Gentles D, Metcalf P, Dyal L, et al. Serum lipid levels for a multicultural population in Auckland, New Zealand: results from the Diabetes, Heart and Health Survey (DHAH) 2002-2003. *NZMJ* 2007;**120**(1265) URL: <http://www.nzma.org.nz/journal/120-1265/2800/>
6. Gentles D, Metcalf P, Dyal L, et al. Metabolic syndrome prevalence in a multicultural population in Auckland, New Zealand. *NZMJ* 2007;**120**(1248) URL: <http://www.nzma.org.nz/journal/120-1248/2387/>
7. Metcalf P, Scragg R, Schaaf D, et al. Trends in major cardiovascular risk factors in Auckland, New Zealand: 1982 to 2002-2003. *NZMJ* 2006;**119**(1245) URL: <http://www.nzma.org.nz/journal/119-1245/2308/>

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
8. Sundborn G, Metcalf P, Scragg R, et al. Ethnic differences in the prevalence of new and known diabetes mellitus, impaired glucose tolerance, and impaired fasting glucose. Diabetes, Heart and Health Survey (DHAH) 2002-2003, Auckland New Zealand. *NZMJ* 2007;**120**(1257) URL: <http://www.nzmj.com/journal/120-1257/2607>
 9. Statistics New Zealand. Census > 2006 Census Data > QuickStats About Auckland Region. (<http://www.stats.govt.nz/Census/2006CensusHomePage/QuickStats/AboutAPlace/SnapShot.aspx?id=1000002&type=region&ParentID=>)
 10. National Health Committee. Rural Health: Challenges of Distance; Opportunities for Innovation. Wellington: Ministry of Health; 2010.
 11. Faatoese A, Pitama S, Gillies T, et al. Community screening for cardiovascular risk factors and levels of treatment in a rural Māori cohort. *Aust N Z J Public Health* 2011; **35**:517-523.
 12. Pitama S, Wells J, Faatoese A, et al. A community cohort study of heart disease in New Zealand with two indigenous samples (rural and urban) and an urban non-indigenous sample: Design, methods, response rates and referral after baseline screening. *Aust NZ J Pub Health* 2011;**35**:249-255.
 13. New Zealand Guidelines Group. New Zealand cardiovascular guidelines handbook: A summary resource for primary care practitioners. 2nd Edition ed. Wellington: Ministry of Health; 2009.
 14. Ioachimescu A, Brennan D, Hoar B, et al. Serum Uric Acid Is an Independent Predictor of All-Cause Mortality in Patients at High Risk of Cardiovascular Disease. *Arthritis Rheum* 2008;**58**(2):623-630.

- 1
2
3 15. Ministry of Health. A Portrait of Health. Key results of the 2006/2007 New Zealand
4 Health Survey. Wellington: Ministry of Health; 2008. Available Online at:
5
6
7 <http://www.moh.govt.nz/moh.nsf/indexmh/portrait-of-health>
8
- 9 16. Brauer G, Prior I. A prospective study of gout in New Zealand Maoris. *Ann Rheum*
10 *Dis* 1978;**37**:466-472.
11
- 12 17. Klemp P, Stansfield S, Castle B, et al. Gout is on the increase in New Zealand. *Ann*
13 *Rheum Dis* 1997;**56**:22-30.
14
- 15 18. Stamp L, Gow P, Sharples K, et al. The optimal use of allopurinol: an audit of
16 allopurinol use in South Auckland. *Aust N Z J Med* 2000;**30**(5):567-572.
17
- 18 19. Simmonds H, McBride M, Hatfield P, et al. Polynesian women are also at risk for
19 hyperuricaemia and gout because of a a genetic defect in renal urate handling. *Br J Rheumatol*
20 1994;**33**(10):932-937.
21
- 22 20. Yang Q, Köttgen A, Dehghan A, et al. Multiple genetic loci influence serum urate
23 levels and their relationship with gout and cardiovascular disease risk factors. *Circ*
24 *Cardiovasc Genet* 2010;**3**:523-530.
25
- 26 21. Hollis-Moffatt J, Xu X, Dalbeth N, et al. Role of the urate transporter SLC2A9 gene in
27 susceptibility to gout in New Zealand Māori, Pacific Island, and Caucasian case-control
28 sample sets. *Arthritis Rheum* 2009;**60**(11):3485-3492.
29
- 30 22. The InterASIA Collaborative Group. Cardiovascular risk factor levels in urban and
31 rural Thailand – The International Collaborative Study of Cardiovascular Disease in Asia
32 (InterASIA). *Eur J Cardiovasc Prev Rehabil* 2003;**10**:249-257.
33
- 34 23. Masterson Creber R, Smeeth L, et al. Physical activity and cardiovascular risk factors
35 among rural and urban groups and rural-to-urban migrants in Peru: a cross-sectional study.
36 *Rev Panam Salud Publica* 2010;**28**(1):1-8.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 24. Wan Q, Harris M, Powell-Davies G, Jayasinghe U, Flack J, Georgiou A, et al.
4
5 Cardiovascular risk levels in general practice patients with type 2 diabetes in rural and urban
6
7 areas. *Aust. J Rural Health* 2007;**15**:327-333.
8
9
10 25. Prior I. A health survey in a rural Maori community, with particular emphasis on the
11
12 cardiovascular, nutritional and metabolic findings. *NZMJ* 1962;**61**(359):333-348.
13
14 26. Prior I, Rose B, Davidson F. Metabolic maladies in New Zealand Maoris. *BMJ*
15
16 1964;**1**:1065-1069.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1 and 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6 and 7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5
		(b) For matched studies, give matching criteria and number of exposed and unexposed	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6 and 7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6 and 7
Bias	9	Describe any efforts to address potential sources of bias	7 (decision support software used)
Study size	10	Explain how the study size was arrived at	5 (previous publication cited)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	7
		(d) If applicable, explain how loss to follow-up was addressed	NA

		(e) Describe any sensitivity analyses	NZ
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	5 (previous publication cited)
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	7
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7, 10-19
		(b) Report category boundaries when continuous variables were categorized	14
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	20
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	23
Generalisability	21	Discuss the generalisability (external validity) of the study results	20-23
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	26

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only



A cohort study comparing cardiovascular risk factors in rural Māori, urban Māori and non-Māori communities in New Zealand

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000799
Article Type:	Research
Date Submitted by the Author:	04-Jan-2012
Complete List of Authors:	Cameron, Vicky; University of Otago, Christchurch, Christchurch Cardioendocrine Research Group Faatoese, Allamanda; University of Otago, Christchurch, Christchurch Cardioendocrine Research Group Gillies, Matea; University of Otago, Christchurch, Māori Indigenous Health Institute Robertson, Paul; University of Otago, Christchurch, Māori Indigenous Health Institute Huria, Tania; University of Otago, Christchurch, Māori Indigenous Health Institute Doughty, Rob; University of Auckland, Department of Medicine Whalley, Gillian; Unitec, Faculty of Social and Health Sciences Richards, Mark; University of Otago, Christchurch, Christchurch Cardioendocrine Research Group Troughton, Richard; University of Otago, Christchurch, Christchurch Cardioendocrine Research Group Tikao-Mason, Karen; University of Otago, Christchurch, Māori Indigenous Health Institute Wells, Elisabeth; University of Otago, Christchurch, Department of Public Health Sheerin, Ian; University of Otago, Christchurch, Department of Public Health Pitama, Suzanne; University of Otago, Christchurch, Māori Indigenous Health Institute
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Cardiovascular risk factors, Indigenous Health, Rural Health

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

A cohort study comparing cardiovascular risk factors in rural Māori, urban Māori and non-Māori communities in New Zealand.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Corresponding Author:

Associate Professor Vicky A Cameron, University of Otago, Christchurch,

PO Box 4345, Christchurch 8140, New Zealand

Phone: +64 3 364 1210 FAX: +64 3 364 0525 Email: Vicky.cameron@otago.ac.nz

Vicky A Cameron¹, Allamanda F Faatoese¹, Matea W Gillies², Paul J Robertson², Tania M Huria², Rob N Doughty³, Gillian A Whalley⁵, A Mark Richards¹, Richard W Troughton¹, Karen N Tikao-Mason², J Elisabeth Wells⁴, Ian G Sheerin⁴, Suzanne G Pitama²

¹ Christchurch Cardioendocrine Research Group, University of Otago, Christchurch 8140, New Zealand;

² Māori Indigenous Health Institute University of Otago, Christchurch 8140, New Zealand

⁴ Department of Public Health, University of Otago, Christchurch 8140, New Zealand

³ Department of Medicine, University of Auckland 1142, New Zealand,

⁵ Faculty of Social and Health Sciences, Unitec, Auckland 1025, New Zealand

Short Title **Cardiovascular risk in rural and urban Māori**

Key Words Indigenous Health; Cardiovascular Diseases; Risk Factors

ABSTRACT

Objectives: To understand health disparities in cardiovascular disease (CVD) in the indigenous Māori of New Zealand, diagnosed and undiagnosed CVD risk factors were compared in rural Māori in an area remote from health services with urban Māori and non-Māori in a city well served with health services.

Design: Prospective cohort study.

Setting: Hauora Manawa is a cohort study of diagnosed and previously undiagnosed CVD, diabetes, and risk factors, based on random selection from electoral rolls of the rural Wairoa District, New Zealand and Christchurch City, New Zealand.

Participants: Screening clinics were attended by 252 rural Māori, 243 urban Māori and 256 urban non-Māori, aged 20 – 64 years.

Main Outcome Measures: The study documented personal and family medical history, blood pressure, anthropometrics, fasting lipids, insulin, glucose, HbA1c, and urate.

Results: Mean age (SD) was 45.7 (11.5) vs 42.6 (11.2) vs 43.6 (11.5) years in rural Māori, urban Māori and non-Māori respectively. Age-adjusted rates of diagnosed cardiac disease were not significantly different across the cohorts (7.5% vs 5.8% vs 2.8%, $P=0.073$). However, rural Māori had significantly higher levels of type-2 diabetes (10.7% vs 3.7% vs 2.4%, $P<0.001$), diagnosed hypertension (25.0% vs 14.9% vs 10.7%, $P<0.001$), treated dyslipidaemia (15.7% vs 7.1% vs 2.8%, $P<0.001$), current smoking (42.8% vs 30.5% vs 15.2%, $P<0.001$) and age-adjusted BMI (30.7 (7.3) vs 29.1 (6.4) vs 26.1±6.4 vs 26.1 (4.5) kg/m², $P<0.001$). Similarly high rates of previously undocumented elevated blood pressure (22.2% vs 23.5% vs 17.6%, $P=0.235$) and high cholesterol (42.1% vs 54.3% vs 42.2%, $P=0.008$) were observed across all cohorts.

Conclusions: Supporting rural general practices to provide intensive screening and management of CVD risk factors would reduce health disparities in the New Zealand indigenous population.

ARTICLE SUMMARY

Article Focus

- The indigenous Māori of New Zealand have high rates of cardiovascular disease (CVD) mortality and morbidity. Current data on the key risk factors underlying this ethnic disparity mostly come from national surveys relying on self-reported diagnoses, or have been collected in New Zealand's largest urban centre, Auckland City.
- This is the first study to screen CVD and associated risk factors concurrently between rural Māori residing in an area remote from health services (Wairoa District), urban Māori in a city well served with secondary and tertiary health services (Christchurch City) and an urban non-Māori cohort.

Key Messages

- We found rural Māori had higher levels of obesity, smoking, hypertension, dyslipidaemia, DM2 and hyperuricaemia than either urban Māori or non-Māori. Thus national health surveys and data collected in large urban centres may significantly underestimate the burden of CVD risk carried by rural Māori.
- Public health initiatives to reduce rates of smoking among rural Māori, along with enhanced implementation of CVD screening in primary care and more intensive clinical management of hypertension, dyslipidaemia and hyperuricaemia would help reduce cardiovascular health disparities in the New Zealand indigenous population.

Strengths and Limitations of the Study

- This study was able to determine current levels of both diagnosed and undiagnosed risk factors within these communities by conducting CVD screening clinics in sectors of the community that are often hard-to-reach. The findings of this study are limited by the relatively small cohort sizes and lack of a rural non-Māori comparator cohort.

INTRODUCTION

The indigenous Māori, comprising approximately 15% of the New Zealand (NZ) population, have high rates of cardiovascular disease (CVD) mortality and morbidity^{1,2}. For the period 1996–1999 CVD mortality among Māori males was 3.0 times higher than that for non-Māori, non-Pacific males and Māori female mortality rates were 4.2 times higher than that for non-Māori, non-Pacific females². Key risk factors underlying the ethnic disparity in CVD have recently been reported in Auckland City, New Zealand's largest urban centre (population approx 1.5 million), using data from general practice clinical databases³ and from community studies⁴⁻⁸. However, three quarters of Māori live outside of Auckland⁹ and nearly 16 percent reside in rural areas. Recent health statistics indicate that ischaemic heart disease rates are higher among those living in rural areas than in urban New Zealanders¹⁰. Furthermore, rural Māori have a shorter life expectancy than urban Māori, with 1.5 years difference for men and 1.2 years difference for women¹⁰, greater than the urban-rural difference in the general population of 0.8 and 0 years for men and women respectively. Life expectancy for rural Māori is less than the overall rural population by 7.2 years for men and 6.6 years for women¹⁰. We have recently reported high levels of both diagnosed and undiagnosed CVD risk factors, especially hypertension, dyslipidaemia and diabetes in a rural Māori community¹¹, with several major risk factors at higher levels than those reported than either national statistics or for Auckland City Māori. To understand how CVD risk factors differ between diverse localities across New Zealand, we have compared the cardiovascular risk profiles of two regionally distinct, rural and urban Māori communities and a matched, urban comparator cohort of non-Māori. This is the first study to screen CVD and associated risk factors concurrently in rural Māori residing in an area remote from health services and in urban Māori in a metropolitan area well served with secondary and tertiary health services.

METHODS

Localities

The Hauora Manawa/ Community Heart Study is a cohort study of heart disease in NZ, based on random selection from electoral rolls, sampled to be representative of the age and gender profiles within each participating Māori community. The Wairoa District is located in rural Hawkes Bay on the North Island of NZ with a population in 2006 of 8481 of whom 61% identified as Māori ethnicity. It is located two hours north by road of the nearest, fully serviced hospital. Christchurch is the largest city in the South Island with a population in 2006 of 348,435, of whom 7.6% identified as Māori, and 75.4% identified as New Zealand European. Christchurch has a large (600-650 bed) tertiary, teaching and research hospital that provides a full range of emergency, acute, elective and outpatient services.

Participants

Full details of kaupapa Māori methodology, sample selection, recruitment and interviewing processes are published elsewhere¹². In brief, participants, aged between 20 to 64 years, stratified by age and sex, were randomly selected from the electoral roll for Wairoa District and for Christchurch City (excluding Banks Peninsula Ward, a largely rural area amalgamated with Christchurch City in 2006). Participants for the Māori samples were selected from among those who identified as being of Māori descent on the roll and who self-identified at interview as being of Māori ethnicity. The Christchurch non-Māori descent selection was frequency matched to the sex- and age-group distribution of the Christchurch Māori descent sample. The overall response rates were 57.6% (95% CI 53.0, 62.2; 254/441) for the Wairoa Māori descent sample, 48.3% (95% CI 44.1, 52.4; 267/553) for the Christchurch Māori descent sample, and 57.2% (95% CI 52.7, 61.8; 257/449; 254/340) for the Christchurch Non-Māori descent sample. The cooperation rates rate (participation among those with whom contact was established) were 74.7% (95% CI 70.1, 79.3) for the Wairoa Māori, 66.6% (95%

1
2 CI 62.0, 71.2; 267/401) for the Christchurch Māori, and 71.4% (95%CI 66.7, 76.1; 257/360)
3
4 for the Christchurch Non-Māori group. The study was approved by the Multi-Region Ethics
5
6 Committee (Reference MEC/06/03026) and all participants provided written, informed
7
8 consent.
9

10 11 12 13 **Screening clinics**

14
15 Screening clinics were held at Wairoa Hospital (May to December 2007) or at the
16
17 Māori/Indigenous Health Institute (MIHI), Christchurch, (January to December 2008), as
18
19 described previously¹¹. In brief, all participants completed an interviewer-administered
20
21 questionnaire providing demographic, personal and family medical history, current
22
23 medications, smoking status recorded as current, ex-smoker (quit more than 12 months) or
24
25 never smoker, alcohol consumption, physical activity levels (physically active defined as “at
26
27 least 30 minutes of moderate or vigorous physical activity on 5 or more days of the week”)
28
29 and socioeconomic data. Blood pressure was recorded (two measurements, seated, at least 20
30
31 minutes apart), height, weight, waist and hip measurements were taken and body mass index
32
33 (BMI) calculated. Body composition analysis was performed by bioimpedance using the
34
35 Tanita Body Composition Analyser, TBF 310 (Tanita Inc, Tokyo, Japan), and the output
36
37 automatically classified participants in the healthy body fat, overweight body fat and obese
38
39 body fat ranges according to age and gender. Fasting blood samples were collected and
40
41 assayed for full blood differential cell counts, plasma lipid profiles, glucose, insulin,
42
43 creatinine, homocysteine, HbA1c and urate (Wairoa Hospital Laboratory, Hawkes Bay
44
45 District Health Board or Canterbury Health Laboratories, Christchurch Hospital).
46
47
48
49
50

51
52
53 A prior cardiac history was defined as a history of diagnosed myocardial infarction, angina,
54
55 heart failure, coronary artery bypass graft (CABG) surgery, percutaneous transluminal
56
57 coronary angioplasty (PTCA), pacemaker, other cardiac intervention or ischaemic stroke.
58
59
60

1
2 Confirmation of prior diagnoses and current management of CVD risk factors were obtained
3
4 from primary care physicians for all participants. A new diagnosis of hypertension and
5
6 dyslipidaemia was made at screening in those with levels above the reference ranges with no
7
8 prior diagnosis and who were not receiving treatment. Hypertension was documented if the
9
10 average of the two blood pressure readings gave a SBP >140mmHg or DBP >90mmHg.
11
12 Dyslipidaemia was diagnosed if the total cholesterol:HDL-cholesterol (TC:HDL) ratio was
13
14 >4.0. The Bestpractice[©] electronic decision support software (Bestpractice[©], 2005 – 2009,
15
16 Dunedin, NZ) was also used to classify participants with metabolic syndrome at screening.
17
18
19
20
21

22 **Statistical analysis**

23
24 All statistical analyses were performed using SPSS v13.0 (Chicago, Illinois, USA). Data are
25
26 expressed as mean (SD) or as percentages. Data collection was complete except for
27
28 anthropometric data for one rural participant. Logistic regression analyses were used to
29
30 compare binary outcomes across the three cohorts and univariate analysis for continuous
31
32 variables, and both unadjusted *P* values and *P* values corrected for age and gender are
33
34 presented. Pairwise comparisons (rural versus urban Māori; urban Māori vs urban non-Māori)
35
36 were carried out using analysis of variance or chi-square tests, as appropriate for continuous
37
38 or discrete variables respectively. For discrete non-binary variables, overall chi-square on a 3
39
40 X 3 table were used followed by a separate 2 X 3 chi-square test for each pairwise
41
42 comparison. Significance levels were set as $P \leq 0.05$.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Baseline characteristics and prior diagnoses

The baseline characteristics of the 751 participants who attended the screening clinics are shown in Table 1. Rural Māori participants, at a mean age of 45.7 years, were older than both urban cohorts (42.6 years and 43.6 years). Comparisons of key risk factors contributing to CVD risk across the three cohorts are described below.

Rates of prior cardiac history showed a non-significant trend to be higher in Māori than non-Māori ($P=0.073$, Table 1). Although age of onset of CVD tended to be lower in urban Māori than either of the other groups, the differences among the three cohorts were not significant (51.8 ± 9.8 vs 43.8 ± 5.7 vs 50.2 ± 8.2 years, $P=0.539$, for rural Māori, urban Māori and urban non-Māori respectively). A prior diagnosis of rheumatic fever had been made in 2% of Wairoa cohort, 0% of urban Māori and 0.4% of urban non-Māori. Of those with a personal cardiac history, 68% of rural Māori, 100% urban Māori and 71% non-Māori reported having first-degree family history of CVD. Overall, including those both with and without a personal cardiac history, the rates of first-degree family history of CVD were 52% rural Māori vs 58% urban Māori vs 55% non-Māori ($P=0.401$).

A prior diagnosis of hypertension was more common in rural Māori than urban non-Māori (Table 1), but not significantly different between the two urban groups, and this was reflected in higher rates of treatment with antihypertensive medications in rural Māori (21.4 vs 11.9 vs 8.6 %, $P<0.001$). Mean systolic (SBP) and diastolic blood pressure (DBP) levels at screening were slightly, but significantly higher in both Māori groups compared to non-Māori.

Table 1. Baseline Characteristics and Cardiovascular Risk Factors in Rural Māori, Urban Māori and Urban Non-Māori

	Rural Māori (N=252) (a)	Urban Māori (N=243) (b)	Non-Māori (N=256) (c)	Overall Unadj <i>P</i> (Adj <i>P</i>)	(a) vs (b) Unadj <i>P</i> (Adj <i>P</i>)	(b) vs (c) Unadj <i>P</i> (Adj <i>P</i>)	(a) vs (c) Unadj <i>P</i> (Adj <i>P</i>)
Age	45.7 (11.5)	42.6 (11.2)	43.6 (11.5)	0.009	0.003	0.339	0.038
Gender, % Female (n)	59.5 (150)	54.7 (133)	51.2 (131)	0.166	0.282	0.426	0.059
Cardiac History*, % (n)	7.5 (19)	5.8 (14)	2.8 (7)	0.066 (0.073)	0.443 (0.942)	0.101 (0.038)	0.020 (0.034)
Hypertension, % (n)	25.0 (63)	14.9 (36)	10.7 (27)	<0.001 (0.001)	0.006 (0.115)	0.157 (0.061)	<0.001 (<0.001)
Systolic Blood Pressure, mmHg, mean (SD)	130.8 (18.5)	128.2 (20.6)	124.5 (14.8)	<0.001 (<0.001)	0.112 (0.074)	0.021 (0.010)	<0.001 (<0.001)
Diastolic Blood Pressure, mmHg, mean (SD)	85.3 (11.1)	86.2 (13.6)	83.0 (12.1)	0.011 (0.002)	0.391 (0.358)	0.004 (0.002)	0.039 (0.028)
Treated Dyslipidaemia, % (n)	15.7 (39)	7.1 (17)	2.8 (7)	<0.001 (<0.001)	0.004 (0.051)	0.032 (0.007)	<0.001 (<0.001)
Total Cholesterol (TC), mmol/L, mean (SD)	5.1 (1.1)	5.2 (1.0)	5.3 (1.1)	0.057 (0.032)	0.112 (0.101)	0.438 (0.423)	0.018 (0.015)

LDL-cholesterol, mmol/L, mean (SD)	3.2 (0.9)	3.3 (0.8)	3.4 (0.9)	0.017 (0.009)	0.042 (0.036)	0.462 (0.449)	0.006 (0.004)
HDL-cholesterol, mmol/L, mean (SD)	1.2 (0.3)	1.2 (0.3)	1.3 (0.3)	<0.001 (<0.001)	0.645 (0.629)	<0.001 (<0.001)	<0.001 (<0.001)
Triglycerides, mmol/L, mean (SD)	1.5 (0.8)	1.4 (1.1)	1.2 (0.7)	0.003 (<0.001)	0.491 (0.474)	0.009 (0.007)	0.001 (0.001)
TC:HDL ratio, mean (SD)	4.2 (1.1)	4.3 (1.1)	4.1 (1.3)	0.221 (0.088)	0.329 (0.305)	0.083 (0.069)	0.484 (0.462)
Urate, mmol/L, mean (SD)	0.338 (0.897)	0.300 (0.093)	0.276 (0.085)	<0.001 (<0.001)	<0.001 (<0.001)	0.003 (0.001)	<0.001 (<0.001)

Continuous variables expressed as means (SD). Adj $P = P$ value adjusted for age and gender.

* Defined as a history of myocardial infarction, angina, heart failure, coronary artery bypass graft (CABG) surgery, percutaneous transluminal coronary angioplasty (PTCA), pacemaker, other cardiac intervention or ischaemic stroke

1
2
3 Rates of previously diagnosed, treated dyslipidaemia were highest in rural Māori, followed by
4
5 urban Māori and lowest in non-Māori (Table 1, $P<0.0001$). However, mean values of the key
6
7 cholesterol variables were above the recommended ranges set by national cardiovascular
8
9 guidelines in all three cohorts ¹³, with urban Māori tending to have the least favourable lipid
10
11 profiles. Urban Māori had higher LDL cholesterol levels than rural Māori although mean
12
13 levels of TC, HDL-cholesterol, triglycerides and TC: HDL ratios did not differ between the
14
15 two Māori communities. Urban Māori also had higher triglycerides and lower HDL
16
17 cholesterol levels compared to non-Māori, while mean levels of TC, LDL-cholesterol and TC:
18
19 HDL ratios were similar between the two urban cohorts.
20
21
22
23
24

25 Plasma urate has been reported to be an independent risk factor for CVD ¹⁴. Plasma urate
26
27 levels were significantly higher in rural Māori than urban Māori, which were also higher than
28
29 in non-Māori (Table 1). Urate levels were above the reference ranges (0.42mmol/L in males
30
31 and 0.37mmol/L in females) in 25% of rural Māori, 10% of urban Māori and 5% non-Māori.
32
33 Previously diagnosed gout was reported by 6% of rural and 4% of urban Māori and 0.4% non-
34
35 Māori. Of those, 56% of rural Māori, 22% urban Māori and 0% non-Māori had plasma urate
36
37 levels above the gender-specific thresholds at screening.
38
39
40
41
42

43 **Metabolic risk factors**

44
45 A prior diagnosis of DM2 (Table 2) was significantly more frequent in rural Māori compared
46
47 to either urban Māori or non-Māori cohorts. In DM2 patients, 48.1% of rural Māori, 66.7%
48
49 urban Māori and 33.3% non-Māori with DM2 had a first-degree family history of DM2.
50
51 Overall, including those with and without DM2, rates of first-degree family history of DM2
52
53 were 43% vs 31% vs 21% non-Māori ($P<0.001$). Metabolic syndrome, diagnosed at
54
55
56
57
58
59
60

1
2
3 screening, was significantly more prevalent in both rural and urban Māori than non-Māori
4
5 (Table 2).
6
7

8
9
10 A gradient in BMI was seen across the three cohorts (Table 2), with both the age-adjusted
11 mean BMI and the proportion with a BMI in the obese range being greatest in rural Māori and
12 lowest in non-Māori. A similar gradient was observed in percent body fat, with more rural
13 Māori classified in the combined overweight and obese percent body fat categories and more
14 urban Māori than non-Māori in these categories ($P<0.001$). In contrast, there was a
15 significantly higher mean fat-free mass in both Māori communities compared to non-Māori.
16
17 The waist to hip ratios were slightly higher in rural Māori than either of the two urban groups
18 ($P=0.005$ to $P<0.001$). The mean levels of the diabetes risk markers (fasting glucose, HbA1c
19 and fasting insulin) were significantly higher in rural Māori than urban Māori, remaining
20 significant after adjusting for gender and age ($P<0.001$), with HbA1c and insulin also higher
21 in urban Māori than non-Māori. Inclusion of BMI into the univariate model accounted for
22 cohort differences in fasting insulin levels and fasting glucose. However, HbA1c levels, even
23 when adjusted for age, gender and BMI, remained significantly higher in rural Māori than
24 urban Māori ($P<0.001$) and higher in urban Māori than non-Māori ($P<0.001$).
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Diabetes, Anthropometrics, Smoking, Alcohol and Physical Activity in Rural Māori, Urban Māori and Urban Non-Māori

	Rural Māori	Urban Māori	Non-Māori	Overall	(a) vs (b)	(b) vs (c)	(a) vs (c)
	(N=252)	(N=243)	(N=256)	Unadj <i>P</i>	Unadj <i>P</i>	Unadj <i>P</i>	Unadj <i>P</i>
	(a)	(b)	(c)	(Adj <i>P</i>)	(Adj <i>P</i>)	(Adj <i>P</i>)	(Adj <i>P</i>)
Type 2 diabetes, % (n)	10.7 (27)	3.7 (9)	2.4 (6)	<0.001 (0.001)	0.004 (0.024)	0.382 (0.279)	0.001 (0.001)
Metabolic Syndrome, % (n)	35.9 (90)	27.1 (65)	14.5 (37)	<0.001 (<0.001)	0.037 (0.139)	0.001 (<0.001)	<0.001 (<0.001)
BMI, mean (SD)	30.7 (7.3)	29.1 (6.4)	26.1 (4.5)	<0.001 (<0.001)	0.004 (0.003)	<0.001 (<0.001)	<0.001 (<0.001)
BMI Categories:							
Healthy BMI % (n)	21.9 (55)	29.2 (71)	45.7 (117)	<0.001	0.079	<0.001	<0.001
Overweight % (n)	30.3 (76)	32.1 (78)	38.3 (98)				
Obese BMI % (n)	47.8 (120)	38.7 (94)	16.0 (41)				
Percent body fat %, mean (SD)	35.0 (10.7)	32.2 (9.4)	28.7 (9.0)	<0.001 (<0.001)	0.001 (<0.001)	<0.001 (<0.001)	<0.001 (<0.001)
Percent body fat categories:							
Healthy body fat % (n)	20.4 (50)	30.5 (73)	41.0 (105)	<0.001	0.066	<0.001	<0.001

Overweight body fat % (n)	25.7 (63)	23.4 (56)	31.6 (81)				
Obese body fat % (n)	51.4 (126)	44.8 (107)	25.0 (64)				
Fat Free Mass, kg, mean (SD)	55.2 (11.2)	55.8 (12.3)	53.8 (10.5)	0.114 (<0.001)	0.534 (0.285)	0.043 (0.001)	0.159 (0.016)
Waist:Hip Ratio, mean (SD)	0.91 (0.08)	0.90 (0.10)	0.89 (0.08)	0.012 (<0.001)	0.034 (0.005)	0.479 (0.351)	0.004 (<0.001)
Glucose, mmol/L, mean (SD)	5.7 (1.7)	5.4 (0.9)	5.3 (0.5)	<0.001 (<0.001)	0.003 (0.002)	0.203 (0.186)	<0.001 (<0.001)
HBA1c, %, mean (SD)	6.3 (1.2)	5.4 (0.7)	5.2 (0.4)	<0.001 (<0.001)	<0.001 (<0.001)	0.002 (0.001)	<0.001 (<0.001)
Insulin, pmol/L, mean (SD)	65.6 (56.9)	52.7 (54.5)	42.7 (34.4)	<0.001 (<0.001)	0.005 (0.005)	0.025 (0.024)	<0.001 (<0.001)
Smoking:							
Current % (n)	42.8 (108)	30.5 (74)	15.2 (39)	<0.001	<0.001	<0.001	<0.001
Ex-smoker % (n)	38.5 (97)	33.3 (81)	29.3 (75)				
Never smoked % (n)	19.0 (48)	36.2 (88)	55.5 (142)				
Cigarette pack years, mean (SD)	5737 (4910)	5469 (5429)	4308 (5760)	0.045 (0.058)	0.615 (0.588)	0.060 (0.042)	0.015 (0.009)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Alcohol Drinkers, % (n)	81.3 (205)	92.2 (224)	91.4 (234)	<0.001	0.001	0.753	0.001
				(0.002)	0.003	0.808	0.005
Physically Active % (n)	68.3 (172)	70.8 (172)	64.8 (166)	0.362	0.157	0.542	0.416
				(0.316)	(0.380)	(0.132)	(0.380)

Continuous variables expressed as means (SD). Adj *P* = *P* value adjusted for age and gender.

Ranges for BMI were healthy range, BMI $\geq 18.5 < 25.0 \text{ kg/m}^2$; overweight, BMI $25.0 - 29.9 \text{ kg/m}^2$; obese $\geq 30.0 \text{ kg/m}^2$. Healthy, overweight and obese body fat ranges calculated using Tanita Body Composition Analyser, TBF 310.

Lifestyle risk factors

Rural Māori had the highest rate of current smoking (Table 2). In both Māori cohorts more females were current smokers and more males were ex-smokers; however there was a trend for males to have a higher calculated number of pack years than females across all three cohorts. Current smokers were of similar mean age (42.0 ± 10.5 vs 41.0 ± 10.7 vs 40.7 ± 12.5 years, $P=0.754$).

Alcohol drinking was significantly less common in rural Māori than either urban Māori or non-Māori ($P=0.002$), but the two urban communities were similar in their proportions of alcohol drinkers. The mean age of current drinkers tended to be similar in all three cohorts (rural Māori 44.5 ± 11.4 vs urban Māori 42.4 ± 11.2 years; non-Māori 43.1 ± 11.4 years, $P=0.153$). Recommended sessional drinking limits (no more than 6 standard drinks per session) were reported to be exceeded daily by 2% rural Māori, 3% urban Māori, 1% non-Māori, weekly by 26% rural Māori, 21% urban Māori and 11% urban non-Māori, monthly or less by 55% rural Māori, 44% urban Māori and 48% non-Māori drinkers.

Physical activity within recommended guidelines was reported by similar proportions of rural Māori, urban Māori and non-Māori (Table 1). Physical activity was not independently associated with any other cardiovascular risk factors.

Almost all participants were registered with a General Practitioner (GP) at the time of screening. Similar proportions of each cohort had visited their doctor within the last 6 months (69% vs 61% vs 66%) or had visited their doctor within the last 12 months (85% vs 74% vs 79%).

Levels of previously undiagnosed hypertension and dyslipidaemia

At screening, approximately 20% of each community were found to have blood pressures above the recommended range (Undiagnosed Hypertension, Table 3). Overall, the combined rates of diagnosed and undiagnosed hypertension across the three cohorts were not significantly different between the two Māori cohorts when adjusted for age, but higher in urban Māori than in non-Māori.

For rural Māori, key risk factors in a logistic regression model for predicting hypertension were gender x age (OR=1.243 (1.061 - 1.155), $P<0.0001$), BMI (OR=1.107 (1.033 - 1.135), $P<0.001$), current smoker (OR=0.461 (0.213 - 0.995), $P=0.049$) and family history of hypertension (OR=2.042 (1.178 - 3.540), $P=0.011$). For urban Māori, key risk factors for predicting hypertension were gender x age (OR=1.257 (1.106 - 1.430), $P<0.0001$), an obese % body fat, (OR=4.394 (2.168 - 8.907), $P<0.0001$) and family history of hypertension (OR=1.972 (1.074 - 3.619), $P=0.029$). Among non-Māori, the interaction of gender x fasting triglyceride levels (OR=1.886 (1.366 - 2.603), $P<0.0001$) and age (OR=1.512 (1.161-1.968), $P=0.002$) were the risk factors significantly associated with having hypertension.

New diagnoses of dyslipidaemia made at screening (Undiagnosed Dyslipidaemia, Table 3) were significantly more common in urban Māori after accounting for age than in either rural Māori or non-Māori. Overall, when diagnosed and undiagnosed dyslipidaemia were combined, over half of each Māori cohort and 45% of non-Māori were dyslipidaemic.

For rural Māori, the only independent risk factor identified in a logistic regression model for predicting dyslipidaemia was waist circumference (OR=1.027 (1.009 - 1.044), $P=0.003$). In urban Māori, dyslipidaemia was predicted by an interaction of gender and BMI (OR=0.960

1
2
3 (0.94 – 0.98, $P<0.0001$, male being protective) and an inverse effect of first-degree family
4
5 history of high cholesterol (OR=0.55 (0.32 – 0.96), $P=0.034$). The interaction of gender x
6
7 BMI was also identified in urban non-Māori; associated with a protective effect in males
8
9 (OR=0.95 (0.93 – 0.97), $P<0.0001$).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Prior and New Diagnoses of Cardiovascular Risk Factors in Rural Māori, Urban Māori and Urban Non-Māori

	Rural Māori	Urban Māori	Non-Māori	Overall	(a) vs (b)	(b) vs (c)	(a) vs (c)
	(a)	(b)	(c)	Unadj <i>P</i>	Unadj <i>P</i>	Unadj <i>P</i>	Unadj <i>P</i>
				(Adj <i>P</i>)	(Adj <i>P</i>)	(Adj <i>P</i>)	(Adj <i>P</i>)
Hypertension:							
Prior Diagnosis Hypertension, %	25.0	14.8	10.5	<0.001	0.006	0.157	<0.001
				(0.001)	(0.115)	(0.061)	(<0.001)
Undiagnosed Hypertension, %	22.2	23.5	17.6	0.235	0.744	0.105	0.191
				(0.124)	(0.744)	(0.054)	(0.109)
Total hypertension, %	47.2	38.3	28.1	<0.001	0.045	0.016	<0.001
				(<0.001)	(0.236)	(0.002)	(<0.001)
Dyslipidaemia:							
Prior Diagnosis Dyslipidaemia, %	15.7	7.1	2.8	<0.001	0.004	0.032	<0.001
				(<0.001)	(0.051)	(0.007)	(<0.001)
Undiagnosed Dyslipidaemia, %	42.6	55.0	42.4	0.008	0.005	0.006	0.961
				(0.004)	(0.014)	(0.002)	(0.570)
Total Dyslipidaemia, %	58.2	62.2	45.6	0.001	0.373	<0.001	0.005
				(<0.001)	(0.261)	(<0.001)	(<0.001)

Undiagnosed = no prior diagnoses or receiving treatment; Total diagnoses = Potential + Previous diagnosis; Adj *P*-value = adjusted for age

DISCUSSION

Cardiovascular disease is the major factor contributing to the ethnic disparities of life expectancy between Māori and non-Māori in NZ, and yet how key risk factors contributing to this discrepancy vary across different localities has not previously been described. To our knowledge, this is the first study to compare current levels of CVD and associated risk factors between two regionally distinct Māori communities; rural Māori residing in an area remote from health services and urban Māori in a city well served with secondary and tertiary health services, as well as non-Māori residing in the same locality. The salient finding was a gradient of cardiovascular risk with the highest burden of CVD risk in rural Māori, particularly obesity, smoking, hypertension, dyslipidaemia, DM2 and hyperuricaemia. Increased measures of body mass were key risk factors associated with the elevated fasting insulin and glucose levels, diagnosed hypertension and dyslipidaemia in both Māori cohorts, but particularly in rural Māori. However, we also observed that undiagnosed hypertension and dyslipidaemia were common across all three New Zealand population groups, despite the establishment of nationwide CVD screening guidelines.

Findings in relation to national statistics

The 2006/07 New Zealand Health Survey documented self-reported health information across the New Zealand population, and included analysis by ethnicity but not by locality¹⁵.

National prevalence rates were comparable to levels of CVD risk factors we observed in urban Māori but would substantially underestimate CVD risk in rural Māori. For example, 13.6% of the national population reported having medicated high blood pressure¹⁵, similar to the 14.9% in our urban Māori but less than the 25% in our rural Māori participants.

Nationwide, one in twelve adults (8.4%) had medicated high cholesterol, comparable to the 7.1% in urban Māori in the current study but less than the 15.7% in rural Māori. The national

1
2
3 prevalence of diagnosed DM2 was 5% in the general population ¹⁵ and 5.8% in Māori (age-
4
5 adjusted) ¹⁵. Rural Māori in the current study had double those rates (10.7%) compared to
6
7 only 3.7% in urban Māori and 2.4% in non-Māori. National rates of smoking remain higher
8
9 in Māori (42.2%) compared to the general New Zealand population (19.9%) ¹⁵. In the current
10
11 study, 42.8% of rural Māori and 30.5% of urban Māori were smokers compared to 15% of
12
13 urban non-Māori. In the New Zealand Health Survey only 50.5% of adults report being
14
15 physically active ¹⁵. In the current study, around 70% of each cohort reported being physically
16
17 active, consistent with national data reporting that Māori are at least as physically active as
18
19 any other ethnic group in New Zealand ¹⁵. It is apparent that the large BMIs and metabolic
20
21 risk factors observed among the Māori participants were not associated with a less active
22
23 lifestyle.
24
25
26
27
28

29 Plasma urate levels, an independent predictor of cardiovascular disease ¹⁴, were above
30
31 reference ranges in 25% of rural Māori and 10% of urban Māori. The national prevalence of
32
33 gout is 1.3%, substantially lower than in the current study, with 6% of rural Māori and 4% of
34
35 urban Māori having been diagnosed by a doctor with gout. It has been known for some
36
37 decades that gout is a common problem in Māori and Pacific Islanders ¹⁶⁻¹⁸ as a result of a
38
39 difference in renal urate handling ¹⁹. Very recently, two genetic variants have been shown to
40
41 have genome-wide significant association with gout ²⁰. One of these, a variant form of the
42
43 renal urate transporter gene, SLC2A9, has been shown to be significantly associated with gout
44
45 in Māori and Pacific Island patients ²¹. Serum urate levels may be an important underlying
46
47 risk factor in Māori and Pacific people.
48
49
50
51
52
53

54 **Findings in relation to other regional studies**

55
56
57
58
59
60

1
2
3 The current community cohort design is comparable with an Auckland study based on cross-
4 sectional sampling, the Diabetes Heart and Health Survey 2002/2003 ⁴⁻⁶. In that study, 37% of
5 Māori and 22% of others had raised blood pressure, with 7% of Māori and 2% of others
6 having previously undetected high blood pressure; more diagnosed but less undiagnosed
7 hypertension than in the current study. Mean total: HDL cholesterol ratios were 4.32 in Māori
8 and 4.04 in others, comparable to our urban Māori and non-Māori cohorts. In addition,
9 approximately 94% of participants had total cholesterol levels above 4.0 mmol/L, similar to
10 the current study (90.7% across all three cohorts); an alarming proportion of each cohort with
11 lipid profiles above recommended ranges. These findings suggest that elevated cholesterol is
12 a key risk factor that is widespread in the New Zealand population and could be more
13 intensively screened and managed throughout primary care. The Auckland prevalence of
14 DM2 was 12% in Māori ⁸, similar rates to the rural Māori, and 3.9% in Europeans similar to
15 both our urban cohorts. Metabolic syndrome was identified in 32% Auckland Māori and 16%
16 of others ⁶. This was less than in our rural Māori sample (35.9%) but similar to our urban
17 cohorts (27.1% and 14.5%). In combination, these data suggest that levels of several risk
18 factors in rural Wairoa Māori exceed those among Māori living in Auckland, especially
19 smoking, undiagnosed hypertension and metabolic syndrome. This contrasts with prior
20 studies from Thailand ²² and Peru ²³, that reported higher metabolic and CVD risk factors in
21 urban dwellers than rural residents. However, in Australia metabolic risk was higher in rural
22 patients with DM2 ²⁴, as in the current study.

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49 The current findings reflect a previous study of metabolic and cardiovascular health in a rural
50 Māori community of the Tuhoe tribe performed fifty years ago ^{25,26}. Prior et al screened 212
51 Tuhoe adults living in the isolated Ruatahuna Valley in the Urewera region ^{25,26}. The study
52 highlighted high rates of coronary heart disease, obesity, high cholesterol, hyperuricaemia,
53
54
55
56
57
58
59
60

1
2
3 clinical gout and diabetes. It is difficult to compare the specific data with the current study, as
4
5 many of the indices measured are no longer in use, such as “relative weight” and the use of
6
7 skin fold measurements to assess body fat. There was a 5% prevalence of rheumatic heart
8
9 disease; considerably higher than the 2% of rural Māori in the current study. Rates of smoking
10
11 were 59% among men and 70% among women, also substantially higher than we observed in
12
13 the rural Wairoa cohort. However, mean blood pressure and rates of DM2 were similar to
14
15 current Wairoa residents. From those findings, alongside the current study, it would appear
16
17 that health issues besetting rural Māori have improved only a little over the past half century.
18
19

20 21 22 23 **Strengths and limitations of the study**

24
25 This study was able to determine current levels of both diagnosed and undiagnosed risk
26
27 factors within these communities by conducting CVD screening clinics in sectors of the
28
29 community that are often hard-to-reach. Prior reports based on areal surveys (usually reliant
30
31 on self-reported diagnoses) or clinical databases may substantially underestimate disease rates
32
33 and risk factors in indigenous population groups who may not have equivalent access to
34
35 health care or CVD screening. The findings of this study are limited by the relatively small
36
37 cohort sizes and lack of a rural non-Māori comparator cohort, the study design being
38
39 constrained by the costs of the in-depth CVD screening.
40
41
42
43
44

45
46 In conclusion, this study reports that compared to either urban Māori or non-Māori, there is a
47
48 greater burden of CVD risk factors, particularly obesity, hypertension, dyslipidaemia, DM2,
49
50 hyperuricaemia and smoking in rural Māori, who have remained largely unstudied for the past
51
52 half-century. Moreover, the findings demonstrate that CVD risk profiles ascertained in
53
54 national health surveys or in New Zealand’s largest metropolitan population do not
55
56 necessarily reflect other localities; Christchurch Māori appear to have lower risk than
57
58
59
60

1
2
3 Auckland Māori, while Māori living in rural Wairoa have substantially higher risk. Despite
4
5 two-thirds of all three cohorts reporting visiting their primary care physicians in the past six to
6
7 twelve months, the study identified similarly high levels of undiagnosed hypertension and
8
9 elevated cholesterol in each of the population samples. Rural Māori participants reported
10
11 similar attendance of participants with their GPs, indicating good engagement with primary
12
13 care and suggesting that higher rates of some risk factors among the rural contingent were not
14
15 necessarily associated with barriers to accessing primary care. However, it seems likely public
16
17 health initiatives to reduce rates of smoking among Māori, along with enhanced
18
19 implementation of CVD screening in primary care and more support for rural general
20
21 practices to provide intensive clinical management of hypertension, dyslipidaemia and
22
23 hyperuricaemia would help reduce the CVD health disparities in the New Zealand indigenous
24
25 population.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGEMENTS:

We express our thanks to the Wairoa Community (Participants and their whanau, Wairoa Taiwhenua, The General Practice Surgeries and Māori Health Providers), the Christchurch Community (Participants and their whanau, Mana whenua ki Waitaha, Pegasus Health and Christchurch Primary Health Care Organisations), and the Māori Advisory Group for the Hauora Manawa project. We are grateful to Professor Gary Nicholls, Dr John Irvine, Dr Cameron Lacey and Wendy Dallas-Katoa for clinical assistance.

COMPETING INTERESTS:

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

CONTRIBUTORS:

VAC and SGP were responsible for the concept and study design, grant writing, supervising recruitment and screening clinics and VAC drafted the manuscript. They are the guarantors. EJW was responsible for overall statistical design, random selection process and contributed to data interpretation. AFF assisted at screening clinics, performed statistical analysis and assisted in drafting the manuscript. MWG, PJR, TMH, RND, GAW, AMR and RWT provided clinical expertise for CVD screening, performed echocardiography (not reported here), interpretation of clinical data and management of referrals for risk factors. KNT-K coordinated the study, especially communication with participants. IGS was involved in study design and edited drafts of the manuscript. All authors had full access to all of the data

1
2
3 (including statistical reports and tables) in the study and can take responsibility for the
4
5 integrity of the data and the accuracy of the data analysis.
6

7 **DATA SHARING:**
8

9 There is no additional data available.
10

11 **FUNDING:**
12

13
14 This work was supported by project grants from the Health Research Council of NZ (Grant
15
16 06/389) and the Heart Foundation of NZ (Project Grant 1273). Additional support was
17
18 provided by PHARMAC, Hawkes Bay District Health Board, Canterbury District Health
19
20 Board, Bestpractice[©] electronic decision support software and Hubbards Cereals (breakfast for
21
22 fasting participants at screening clinics).
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Ajwani S, Blakely T, Robson B, et al. Decades of Disparity: Ethnic mortality trends in New Zealand 1980 -1999. Public Health Intelligence 2003; Occasional Bulletin Number 16. Wellington: Ministry of Health and University of Otago; 2003.
2. Bramley D, Riddell T, Crengle S, et al. A call to action on Maori cardiovascular health. *NZMJ* 2004;**117**(1197) URL: <http://www.nzma.org.nz/journal/117-1197/957/>
3. Riddell T, Jackson R, Wells S, et al. Assessing Maori/non-Maori differences in cardiovascular disease risk and risk management in routine primary care practice using web-based clinical decision support: (PREDICT CVD-2). *NZMJ* 2007;**120**(1250) URL: <http://www.nzma.org.nz/journal/120-1250/2445/>
4. Gentles D, Metcalf P, Dyal L, et al. Blood pressure prevalences and levels for a multicultural population in Auckland, New Zealand: results from the Diabetes, Heart and Health Survey 2002/2003. *NZMJ* 2006;**119**(1245) URL: <http://www.nzma.org.nz/journal/119-1245/2318/>
5. Gentles D, Metcalf P, Dyal L, et al. Serum lipid levels for a multicultural population in Auckland, New Zealand: results from the Diabetes, Heart and Health Survey (DHAH) 2002-2003. *NZMJ* 2007;**120**(1265) URL: <http://www.nzma.org.nz/journal/120-1265/2800/>
6. Gentles D, Metcalf P, Dyal L, et al. Metabolic syndrome prevalence in a multicultural population in Auckland, New Zealand. *NZMJ* 2007;**120**(1248) URL: <http://www.nzma.org.nz/journal/120-1248/2387/>
7. Metcalf P, Scragg R, Schaaf D, et al. Trends in major cardiovascular risk factors in Auckland, New Zealand: 1982 to 2002-2003. *NZMJ* 2006;**119**(1245) URL: <http://www.nzma.org.nz/journal/119-1245/2308/>

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
8. Sundborn G, Metcalf P, Scragg R, et al. Ethnic differences in the prevalence of new and known diabetes mellitus, impaired glucose tolerance, and impaired fasting glucose. Diabetes, Heart and Health Survey (DHAH) 2002-2003, Auckland New Zealand. *NZMJ* 2007;**120**(1257) URL: <http://www.nzmj.com/journal/120-1257/2607>
 9. Statistics New Zealand. Census > 2006 Census Data > QuickStats About Auckland Region. (<http://www.stats.govt.nz/Census/2006CensusHomePage/QuickStats/AboutAPlace/SnapShot.aspx?id=1000002&type=region&ParentID=>)
 10. National Health Committee. Rural Health: Challenges of Distance; Opportunities for Innovation. Wellington: Ministry of Health; 2010.
 11. Faatoese A, Pitama S, Gillies T, et al. Community screening for cardiovascular risk factors and levels of treatment in a rural Māori cohort. *Aust N Z J Public Health* 2011; **35**:517-523.
 12. Pitama S, Wells J, Faatoese A, et al. A community cohort study of heart disease in New Zealand with two indigenous samples (rural and urban) and an urban non-indigenous sample: Design, methods, response rates and referral after baseline screening. *Aust NZ J Pub Health* 2011;**35**:249-255.
 13. New Zealand Guidelines Group. New Zealand cardiovascular guidelines handbook: A summary resource for primary care practitioners. 2nd Edition ed. Wellington: Ministry of Health; 2009.
 14. Ioachimescu A, Brennan D, Hoar B, et al. Serum Uric Acid Is an Independent Predictor of All-Cause Mortality in Patients at High Risk of Cardiovascular Disease. *Arthritis Rheum* 2008;**58**(2):623-630.

- 1
2
3 15. Ministry of Health. A Portrait of Health. Key results of the 2006/2007 New Zealand
4 Health Survey. Wellington: Ministry of Health; 2008. Available Online at:
5
6
7 <http://www.moh.govt.nz/moh.nsf/indexmh/portrait-of-health>
8
- 9 16. Brauer G, Prior I. A prospective study of gout in New Zealand Maoris. *Ann Rheum*
10 *Dis* 1978;**37**:466-472.
11
- 12 17. Klemp P, Stansfield S, Castle B, et al. Gout is on the increase in New Zealand. *Ann*
13 *Rheum Dis* 1997;**56**:22-30.
14
- 15 18. Stamp L, Gow P, Sharples K, et al. The optimal use of allopurinol: an audit of
16 allopurinol use in South Auckland. *Aust N Z J Med* 2000;**30**(5):567-572.
17
- 18 19. Simmonds H, McBride M, Hatfield P, et al. Polynesian women are also at risk for
19 hyperuricaemia and gout because of a a genetic defect in renal urate handling. *Br J Rheumatol*
20 1994;**33**(10):932-937.
21
- 22 20. Yang Q, Köttgen A, Dehghan A, et al. Multiple genetic loci influence serum urate
23 levels and their relationship with gout and cardiovascular disease risk factors. *Circ*
24 *Cardiovasc Genet* 2010;**3**:523-530.
25
- 26 21. Hollis-Moffatt J, Xu X, Dalbeth N, et al. Role of the urate transporter SLC2A9 gene in
27 susceptibility to gout in New Zealand Māori, Pacific Island, and Caucasian case-control
28 sample sets. *Arthritis Rheum* 2009;**60**(11):3485-3492.
29
- 30 22. The InterASIA Collaborative Group. Cardiovascular risk factor levels in urban and
31 rural Thailand – The International Collaborative Study of Cardiovascular Disease in Asia
32 (InterASIA). *Eur J Cardiovasc Prev Rehabil* 2003;**10**:249-257.
33
- 34 23. Masterson Creber R, Smeeth L, et al. Physical activity and cardiovascular risk factors
35 among rural and urban groups and rural-to-urban migrants in Peru: a cross-sectional study.
36 *Rev Panam Salud Publica* 2010;**28**(1):1-8.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 24. Wan Q, Harris M, Powell-Davies G, Jayasinghe U, Flack J, Georgiou A, et al.
4
5 Cardiovascular risk levels in general practice patients with type 2 diabetes in rural and urban
6
7 areas. *Aust. J Rural Health* 2007;**15**:327-333.
8
9
10 25. Prior I. A health survey in a rural Maori community, with particular emphasis on the
11
12 cardiovascular, nutritional and metabolic findings. *NZMJ* 1962;**61**(359):333-348.
13
14 26. Prior I, Rose B, Davidson F. Metabolic maladies in New Zealand Maoris. *BMJ*
15
16 1964;**1**:1065-1069.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1 and 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6 and 7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5
		(b) For matched studies, give matching criteria and number of exposed and unexposed	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6 and 7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6 and 7
Bias	9	Describe any efforts to address potential sources of bias	7 (decision support software used)
Study size	10	Explain how the study size was arrived at	5 (previous publication cited)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	7
		(d) If applicable, explain how loss to follow-up was addressed	NA

		(e) Describe any sensitivity analyses	NZ
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	5 (previous publication cited)
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	7
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7, 10-19
		(b) Report category boundaries when continuous variables were categorized	14
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	20
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	23
Generalisability	21	Discuss the generalisability (external validity) of the study results	20-23
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	26

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only



A cohort study comparing cardiovascular risk factors in rural Māori, urban Māori and non-Māori communities in New Zealand

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000799.R2
Article Type:	Research
Date Submitted by the Author:	11-May-2012
Complete List of Authors:	Cameron, Vicky; University of Otago, Christchurch, Christchurch Cardioendocrine Research Group Faatoese, Allamanda; University of Otago, Christchurch, Christchurch Cardioendocrine Research Group Gillies, Matea; University of Otago, Christchurch, Māori Indigenous Health Institute Robertson, Paul; University of Otago, Christchurch, Māori Indigenous Health Institute Huria, Tania; University of Otago, Christchurch, Māori Indigenous Health Institute Doughty, Rob; University of Auckland, Department of Medicine Whalley, Gillian; Unitec, Faculty of Social and Health Sciences Richards, Mark; University of Otago, Christchurch, Christchurch Cardioendocrine Research Group Troughton, Richard; University of Otago, Christchurch, Christchurch Cardioendocrine Research Group Tikao-Mason, Karen; University of Otago, Christchurch, Māori Indigenous Health Institute Wells, Elisabeth; University of Otago, Christchurch, Department of Public Health Sheerin, Ian; University of Otago, Christchurch, Department of Public Health Pitama, Suzanne; University of Otago, Christchurch, Māori Indigenous Health Institute
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Cardiovascular risk factors, Indigenous Health, Rural Health

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

A cohort study comparing cardiovascular risk factors in rural Māori, urban Māori and non-Māori communities in New Zealand.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Corresponding Author:

Associate Professor Vicky A Cameron, University of Otago, Christchurch,

PO Box 4345, Christchurch 8140, New Zealand

Phone: +64 3 364 1210 FAX: +64 3 364 0525 Email: Vicky.cameron@otago.ac.nz

Vicky A Cameron¹, Allamanda F Faatoese¹, Matea W Gillies², Paul J Robertson², Tania M Huria², Rob N Doughty³, Gillian A Whalley⁵, A Mark Richards¹, Richard W Troughton¹, Karen N Tikao-Mason², J Elisabeth Wells⁴, Ian G Sheerin⁴, Suzanne G Pitama²

¹ Christchurch Cardioendocrine Research Group, University of Otago, Christchurch 8140, New Zealand;

² Māori Indigenous Health Institute University of Otago, Christchurch 8140, New Zealand

⁴ Department of Public Health, University of Otago, Christchurch 8140, New Zealand

³ Department of Medicine, University of Auckland 1142, New Zealand,

⁵ Faculty of Social and Health Sciences, Unitec, Auckland 1025, New Zealand

Short Title **Cardiovascular risk in rural and urban Māori**

Key Words Indigenous Health; Cardiovascular Diseases; Risk Factors

ABSTRACT

Objectives: To understand health disparities in cardiovascular disease (CVD) in the indigenous Māori of New Zealand, diagnosed and undiagnosed CVD risk factors were compared in rural Māori in an area remote from health services with urban Māori and non-Māori in a city well served with health services.

Design: Prospective cohort study.

Setting: Hauora Manawa is a cohort study of diagnosed and previously undiagnosed CVD, diabetes, and risk factors, based on random selection from electoral rolls of the rural Wairoa District and Christchurch City, New Zealand.

Participants: Screening clinics were attended by 252 rural Māori, 243 urban Māori and 256 urban non-Māori, aged 20 – 64 years.

Main Outcome Measures: The study documented personal and family medical history, blood pressure, anthropometrics, fasting lipids, insulin, glucose, HbA1c, and urate, to identify risk factors in common and those that differ among the three communities.

Results: Mean age (SD) was 45.7 (11.5) vs 42.6 (11.2) vs 43.6 (11.5) years in rural Māori, urban Māori and non-Māori respectively. Age-adjusted rates of diagnosed cardiac disease were not significantly different across the cohorts (7.5% vs 5.8% vs 2.8%, $P=0.073$). However, rural Māori had significantly higher levels of type-2 diabetes (10.7% vs 3.7% vs 2.4%, $P<0.001$), diagnosed hypertension (25.0% vs 14.9% vs 10.7%, $P<0.001$), treated dyslipidaemia (15.7% vs 7.1% vs 2.8%, $P<0.001$), current smoking (42.8% vs 30.5% vs 15.2%, $P<0.001$) and age-adjusted BMI (30.7 (7.3) vs 29.1 (6.4) vs 26.1 (4.5) kg/m^2 , $P<0.001$). Similarly high rates of previously undocumented elevated blood pressure (22.2% vs 23.5% vs 17.6%, $P=0.235$) and high cholesterol (42.1% vs 54.3% vs 42.2%, $P=0.008$) were observed across all cohorts.

Conclusions: Supporting integrated rural healthcare to provide screening and management of CVD risk factors would reduce health disparities in this indigenous population.

INTRODUCTION

The indigenous Māori, comprising approximately 15% of the New Zealand (NZ) population, have high rates of cardiovascular disease (CVD) mortality and morbidity^{1,2}. Life expectancy for Māori is less than the overall population by 8.6 years for men and 7.9 years for women³ and cardiovascular disease is the leading cause of death.¹ For the period 1996–1999 CVD mortality among Māori males was 3.0 times higher than that for non-Māori, non-Pacific males and Māori female mortality rates were 4.2 times higher than that for non-Māori, non-Pacific females². Key risk factors underlying the ethnic disparity in CVD have recently been reported in Auckland City, New Zealand’s largest urban centre (population approximately 1.5 million), using data from general practice clinical databases⁴ and from community studies⁵⁻⁹. However, three quarters of Māori live outside of Auckland¹⁰ and nearly 16 percent reside in rural areas. Recent health statistics indicate that ischaemic heart disease rates are higher among those living in rural areas than in urban New Zealanders¹¹. Furthermore, rural Māori have an even shorter life expectancy than urban Māori, with 1.5 years difference for men and 1.2 years difference for women¹¹, greater than the urban-rural difference in the general population of 0.8 and 0 years for men and women respectively.¹¹ Rural non-Māori do not necessarily share the same levels of deprivation as rural Māori. In areas classified as “Highly Rural/Remote,” almost half (46%) of deprivation quintile five residents are Māori.¹¹ No studies to date have compared cardiovascular health and risk factors between rural and urban Māori communities, and the only previous study of cardiovascular health in rural Māori was conducted 50 years ago.¹²

We have recently reported high levels of both diagnosed and undiagnosed CVD risk factors, especially hypertension, dyslipidaemia and diabetes in a rural Māori community¹³, with several major risk factors at higher levels than those reported than either national statistics or for Auckland City Māori. To understand how CVD risk factors differ between diverse

1
2 localities across New Zealand, we have compared the cardiovascular risk profiles of two
3
4 regionally distinct, rural and urban Māori communities and a matched, urban comparator
5
6 cohort of non-Māori, to identify risk factors in common and those that differ among these
7
8 communities. This is the first study to screen CVD and associated risk factors concurrently in
9
10 rural Māori residing in an area remote from health services and in urban Māori in a
11
12 metropolitan area well served with secondary and tertiary health services.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Localities

The Hauora Manawa/ Community Heart Study is a cohort study of heart disease in NZ, based on random selection from electoral rolls, sampled to be representative of the age and gender profiles within each participating Māori community. The intention was to select two Māori communities as diverse from each other as possible. The Wairoa District is located in rural Hawkes Bay on the North Island of NZ with a population in 2006 of 8481 of whom 61% identified as Māori ethnicity. It is located two hours north by road of the nearest, fully serviced hospital. Using the Statistics New Zealand definition of rural that uses workplace area meshblocks to allocate a district to one of four categories¹⁴, based on employment location as the defining variable, Wairoa District is classified in part “Rural Area with Low Urban Influence” and part “Highly Rural//Remote Area.” Wairoa is one of three regions in New Zealand where Māori make up over 60% of the local population.¹⁵ The district has associated socioeconomic deprivation and issues of health care access. Māori in Wairoa have a median income of \$18,500 (compared with a median of \$20,900 for all Māori and \$24,400 for all of New Zealand).¹⁵ A matched non-Māori sample was not recruited from the small non-Māori population because of differing demographics between the two ethnic groups, especially the younger population profile of Māori. Operating under the umbrella of the Hawkes Bay District Health Board (HBDHB), which also manages the local hospital situated in the city of Hastings, primary healthcare in Wairoa at the time of the study consisted of four general medical practices, all located within Wairoa township and administered by a single Primary Healthcare Organisation (PHO). In addition, there were four Māori health providers across the Wairoa District, providing health support services.

In contrast, Christchurch is the largest city in the South Island with a population in 2006 of 348,435, of whom 7.6% identified as Māori, and 75.4% identified as New Zealand European.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Christchurch city has a large (600-650 bed) tertiary, teaching and research hospital that provides a full range of emergency, acute, elective and outpatient services. Socioeconomic differences between the Māori and non-Māori urban populations were not so marked, with median income levels for Māori being \$22,000 versus \$23,400 for the Christchurch population overall. ¹⁶ Operating under the umbrella of the Canterbury District Health Board (CDHB), primary healthcare in Christchurch City is administered by two PHOs, with approximately 100 member general practices and ten additional Māori health providers.

Participants

Full details of, sample selection, recruitment, interviewing processes and kaupapa Māori methodology are published elsewhere ¹⁷. In brief, participants, aged between 20 to 64 years, stratified by age and sex, were randomly selected from the combined general and Māori electoral rolls for Wairoa District and for Christchurch City (excluding Banks Peninsula Ward, a largely rural area amalgamated with Christchurch City in 2006). The New Zealand electoral rolls have 93.44% enrolment of the eligible population, are updated every 3 years ¹⁸ and were thought to provide the best sampling frame for this study as it allowed selection of targeted age and gender samples of specific ethnic Māori and non-Māori descent. Participants for the Māori samples were selected from among those who identified as being of Māori descent on the roll and who also self-identified at interview as being of Māori ethnicity. Since 1986, self-identification of ethnicity has become the standard practice in New Zealand government, health and research documentation ^{19, 20} and participants in this study were asked the ethnicity question as in the New Zealand Census. In the census, people can report multiple ethnicities, and anyone listing Māori is counted as Māori under both prioritised and total response analyses. The Christchurch non-Māori descent selection was frequency matched to the sex- and age-group distribution of the Christchurch Māori descent sample. The overall response rates were 57.6% (95% CI 53.0, 62.2; 254/441) for the Wairoa Māori descent

1
2 sample, 48.3% (95% CI 44.1, 52.4; 267/553) for the Christchurch Māori descent sample, and
3
4 57.2% (95% CI 52.7, 61.8; 257/449; 254/340) for the Christchurch Non-Māori descent
5
6 sample. The cooperation rates rate (participation among those with whom contact was
7
8 established) were 74.7% (95% CI 70.1, 79.3) for the Wairoa Māori, 66.6% (95% CI 62.0,
9
10 71.2; 267/401) for the Christchurch Māori, and 71.4% (95%CI 66.7, 76.1; 257/360) for the
11
12 Christchurch Non-Māori group.
13
14

15
16
17
18 The current study was unique in that it integrated elements of biomedical CVD research
19
20 design, such as recruitment by random selection (not consistent with Māori cultural processes
21
22 in which tribal leaders would select participants) within a kaupapa Māori framework.
23

24
25 Kaupapa Maori research provides a structure in which Māori worldview is the norm.²¹ The
26
27 following aspects of kaupapa Māori research were incorporated in the Hauora Manawa Study:

28
29 The project was Māori led and controlled (Lead Investigator was Suzanne Pitama, Ngati
30
31 Kahugnunu ki Wairoa); the research objectives were based on Māori values, beliefs and
32
33 experiences and were validated by the Māori communities who were the focus of the study;
34
35 the research had to demonstrate benefit to the community; joint ownership of the
36
37 data/information was negotiated between researchers and participants/communities.; the
38
39 research team was accountable to the communities from which the information was gathered;
40
41 appropriate analysis was employed to minimise dominant cultural biases.
42
43
44
45

46
47 The study was approved by the Multi-Region Ethics Committee (Reference MEC/06/03026)
48
49 and all participants provided written, informed consent.
50
51

52 53 **Screening clinics**

54
55 Screening clinics were held at Wairoa Hospital (May to December 2007) or at the
56
57 Māori/Indigenous Health Institute (MIHI), Christchurch, (January to December 2008), as
58
59
60

1
2 described previously¹³. In brief, all participants completed an interviewer-administered
3
4 questionnaire providing demographic, personal and family medical history, current
5
6 medications, smoking status recorded as current, ex-smoker (quit more than 12 months) or
7
8 never smoker, alcohol consumption, physical activity levels (physically active defined as “at
9
10 least 30 minutes of moderate or vigorous physical activity on 5 or more days of the week”)
11
12 and socioeconomic data. Blood pressure was recorded (two measurements, seated, at least 20
13
14 minutes apart), height, weight, waist and hip measurements were taken and body mass index
15
16 (BMI) calculated. Body composition analysis was performed by bioimpedance using the
17
18 Tanita Body Composition Analyser, TBF 310 (Tanita Inc, Tokyo, Japan), and the output
19
20 automatically classified participants in the healthy body fat, overweight body fat and obese
21
22 body fat ranges according to age and gender. Fasting blood samples were collected and
23
24 assayed for full blood differential cell counts, plasma lipid profiles, glucose, insulin,
25
26 creatinine, homocysteine, HbA1c and urate (Wairoa Hospital Laboratory, Hawkes Bay
27
28 District Health Board or Canterbury Health Laboratories, Christchurch Hospital).
29
30
31
32
33
34

35
36 A prior cardiac history was defined as a history of diagnosed myocardial infarction, angina,
37
38 heart failure, coronary artery bypass graft (CABG) surgery, percutaneous transluminal
39
40 coronary angioplasty (PTCA), pacemaker, other cardiac intervention or ischaemic stroke.
41
42 Confirmation of prior diagnoses and current management of CVD risk factors were obtained
43
44 from primary care physicians for all participants. A new diagnosis of hypertension and
45
46 dyslipidaemia was made at screening in those with levels above the reference ranges with no
47
48 prior diagnosis and who were not receiving treatment. Hypertension was documented if the
49
50 average of the two blood pressure readings gave a SBP >140mmHg or DBP >90mmHg.
51
52 Dyslipidaemia was diagnosed if the total cholesterol:HDL-cholesterol (TC:HDL) ratio was
53
54 >4.0. The Bestpractice[®] electronic decision support software (Bestpractice[®], 2005 – 2009,
55
56 Dunedin, NZ) was used to calculate 5 year CVD risk scores according to the New Zealand
57
58
59
60

1
2 CVD Risk Guidelines²² and was also used to classify participants with metabolic syndrome
3
4 at screening.
5
6
7

8 9 **Statistical analysis**

10 All statistical analyses were performed using SPSS v13.0 (Chicago, Illinois, USA). Data are
11 expressed as mean (SD) or as percentages. Data collection was complete except for
12 anthropometric data for one rural participant. Logistic regression analyses were used to
13 compare binary outcomes across the three cohorts and univariate analysis for continuous
14 variables, and both unadjusted *P* values and *P* values corrected for age and gender are
15 presented. Pairwise comparisons (rural versus urban Māori; urban Māori vs urban non-Māori)
16 were carried out using analysis of variance or chi-square tests, as appropriate for continuous
17 or discrete variables respectively. For discrete non-binary variables, overall chi-square on a 3
18 X 3 table were used followed by a separate 2 X 3 chi-square test for each pairwise
19 comparison. Significance levels were set as $P \leq 0.05$.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Baseline characteristics and prior diagnoses

The baseline characteristics of the 751 participants who attended the screening clinics are shown in Table 1. Rural Māori participants, at a mean age of 45.7 years, were older than both urban cohorts (42.6 years and 43.6 years). Comparisons of key risk factors contributing to CVD risk across the three cohorts are described below.

Rates of prior cardiac history showed a non-significant trend to be higher in Māori than non-Māori ($P=0.073$, Table 1). Although age of onset of CVD tended to be lower in urban Māori than either of the other groups, the differences among the three cohorts were not significant (51.8 ± 9.8 vs 43.8 ± 5.7 vs 50.2 ± 8.2 years, $P=0.539$, for rural Māori, urban Māori and urban non-Māori respectively). A prior diagnosis of rheumatic fever had been made in 2% of Wairoa cohort, 0% of urban Māori and 0.4% of urban non-Māori. Of those with a personal cardiac history, 68% of rural Māori, 100% urban Māori and 71% non-Māori reported having first-degree family history of CVD. Overall, including those both with and without a personal cardiac history, the rates of first-degree family history of CVD were 52% rural Māori vs 58% urban Māori vs 55% non-Māori ($P=0.401$).

A prior diagnosis of hypertension was more common in rural Māori than urban non-Māori (Table 1), but not significantly different between the two urban groups, and this was reflected in higher rates of treatment with antihypertensive medications in rural Māori (21.4 vs 11.9 vs 8.6 %, $P<0.001$). Mean systolic (SBP) and diastolic blood pressure (DBP) levels at screening were slightly, but significantly higher in both Māori groups compared to non-Māori.

Table 1. Baseline Characteristics and Cardiovascular Risk Factors in Rural Māori, Urban Māori and Urban Non-Māori

	Rural Māori (N=252) (a)	Urban Māori (N=243) (b)	Non-Māori (N=256) (c)	Overall Unadj <i>P</i> (Adj <i>P</i>)	(a) vs (b) Unadj <i>P</i> (Adj <i>P</i>)	(b) vs (c) Unadj <i>P</i> (Adj <i>P</i>)	(a) vs (c) Unadj <i>P</i> (Adj <i>P</i>)
Age	45.7 (11.5)	42.6 (11.2)	43.6 (11.5)	0.009	0.003	0.339	0.038
Gender, % Female (n)	59.5 (150)	54.7 (133)	51.2 (131)	0.166	0.282	0.426	0.059
Cardiac History*, % (n)	7.5 (19)	5.8 (14)	2.8 (7)	0.066 (0.073)	0.443 (0.942)	0.101 (0.038)	0.020 (0.034)
Hypertension, % (n)	25.0 (63)	14.9 (36)	10.7 (27)	<0.001 (0.001)	0.006 (0.115)	0.157 (0.061)	<0.001 (<0.001)
Systolic Blood Pressure, mmHg, mean (SD)	130.8 (18.5)	128.2 (20.6)	124.5 (14.8)	<0.001 (<0.001)	0.112 (0.074)	0.021 (0.010)	<0.001 (<0.001)
Diastolic Blood Pressure, mmHg, mean (SD)	85.3 (11.1)	86.2 (13.6)	83.0 (12.1)	0.011 (0.002)	0.391 (0.358)	0.004 (0.002)	0.039 (0.028)
Treated Dyslipidaemia, % (n)	15.7 (39)	7.1 (17)	2.8 (7)	<0.001 (<0.001)	0.004 (0.051)	0.032 (0.007)	<0.001 (<0.001)
Total Cholesterol (TC), mmol/L, mean (SD)	5.1 (1.1)	5.2 (1.0)	5.3 (1.1)	0.057 (0.032)	0.112 (0.101)	0.438 (0.423)	0.018 (0.015)

LDL-cholesterol, mmol/L, mean (SD)	3.2 (0.9)	3.3 (0.8)	3.4 (0.9)	0.017 (0.009)	0.042 (0.036)	0.462 (0.449)	0.006 (0.004)
HDL-cholesterol, mmol/L, mean (SD)	1.2 (0.3)	1.2 (0.3)	1.3 (0.3)	<0.001 (<0.001)	0.645 (0.629)	<0.001 (<0.001)	<0.001 (<0.001)
Triglycerides, mmol/L, mean (SD)	1.5 (0.8)	1.4 (1.1)	1.2 (0.7)	0.003 (<0.001)	0.491 (0.474)	0.009 (0.007)	0.001 (0.001)
TC:HDL ratio, mean (SD)	4.2 (1.1)	4.3 (1.1)	4.1 (1.3)	0.221 (0.088)	0.329 (0.305)	0.083 (0.069)	0.484 (0.462)
Urate, mmol/L, mean (SD)	0.338 (0.897)	0.300 (0.093)	0.276 (0.085)	<0.001 (<0.001)	<0.001 (<0.001)	0.003 (0.001)	<0.001 (<0.001)

Continuous variables expressed as means (SD). Adj $P = P$ value adjusted for age and gender.

* Defined as a history of myocardial infarction, angina, heart failure, coronary artery bypass graft (CABG) surgery, percutaneous transluminal coronary angioplasty (PTCA), pacemaker, other cardiac intervention or ischaemic stroke

1
2
3 Rates of previously diagnosed, treated dyslipidaemia were highest in rural Māori, followed by
4
5 urban Māori and lowest in non-Māori (Table 1, $P<0.0001$). However, mean values of the key
6
7 cholesterol variables were above the recommended ranges set by national cardiovascular
8
9 guidelines in all three cohorts ²², with urban Māori tending to have the least favourable lipid
10
11 profiles. Urban Māori had higher LDL cholesterol levels than rural Māori although mean
12
13 levels of TC, HDL-cholesterol, triglycerides and TC: HDL ratios did not differ between the
14
15 two Māori communities. Urban Māori also had higher triglycerides and lower HDL
16
17 cholesterol levels compared to non-Māori, while mean levels of TC, LDL-cholesterol and TC:
18
19 HDL ratios were similar between the two urban cohorts.
20
21
22
23
24

25 Plasma urate has been reported to be an independent risk factor for CVD ²³. Plasma urate
26
27 levels were significantly higher in rural Māori than urban Māori, which were also higher than
28
29 in non-Māori (Table 1). Urate levels were above the reference ranges (0.42mmol/L in males
30
31 and 0.37mmol/L in females) in 25% of rural Māori, 10% of urban Māori and 5% non-Māori.
32
33 Previously diagnosed gout was reported by 6% of rural and 4% of urban Māori and 0.4% non-
34
35 Māori. Of those, 56% of rural Māori, 22% urban Māori and 0% non-Māori had plasma urate
36
37 levels above the gender-specific thresholds at screening.
38
39
40
41
42

43 **Metabolic risk factors**

44
45 A prior diagnosis of DM2 (Table 2) was significantly more frequent in rural Māori compared
46
47 to either urban Māori or non-Māori cohorts. In DM2 patients, 48.1% of rural Māori, 66.7%
48
49 urban Māori and 33.3% non-Māori with DM2 had a first-degree family history of DM2.
50
51 Overall, including those with and without DM2, rates of first-degree family history of DM2
52
53 were 43% rural Māori vs 31% urban Māori vs 21% non-Māori ($P<0.001$). Metabolic
54
55
56
57
58
59
60

1
2
3 syndrome, diagnosed at screening, was significantly more prevalent in both rural and urban
4
5 Māori than non-Māori (Table 2).
6
7

8
9 A gradient in BMI was seen across the three cohorts (Table 2), with both the age-adjusted
10 mean BMI and the proportion with a BMI in the obese range being greatest in rural Māori and
11 lowest in non-Māori. A similar gradient was observed in percent body fat, with more rural
12 Māori classified in the combined overweight and obese percent body fat categories and more
13 urban Māori than non-Māori in these categories ($P<0.001$). In contrast, there was a
14 significantly higher mean fat-free mass in both Māori communities compared to non-Māori.
15
16 The waist to hip ratios were slightly higher in rural Māori than either of the two urban groups
17 ($P=0.005$ to $P<0.001$). The mean levels of the diabetes risk markers (fasting glucose, HbA1c
18 and fasting insulin) were significantly higher in rural Māori than urban Māori, remaining
19 significant after adjusting for gender and age ($P<0.001$), with HbA1c and insulin also higher
20 in urban Māori than non-Māori. Inclusion of BMI into the univariate model accounted for
21 cohort differences in fasting insulin levels and fasting glucose. However, HbA1c levels, even
22 when adjusted for age, gender and BMI, remained significantly higher in rural Māori than
23 urban Māori ($P<0.001$) and higher in urban Māori than non-Māori ($P<0.001$).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Diabetes, Anthropometrics, Smoking, Alcohol and Physical Activity in Rural Māori, Urban Māori and Urban Non-Māori

	Rural Māori	Urban Māori	Non-Māori	Overall	(a) vs (b)	(b) vs (c)	(a) vs (c)
	(N=252)	(N=243)	(N=256)	Unadj P	Unadj P	Unadj P	Unadj P
	(a)	(b)	(c)	(Adj P)	(Adj P)	(Adj P)	(Adj P)
Type 2 diabetes, % (n)	10.7 (27)	3.7 (9)	2.4 (6)	<0.001 (0.001)	0.004 (0.024)	0.382 (0.279)	0.001 (0.001)
Metabolic Syndrome, % (n)	35.9 (90)	27.1 (65)	14.5 (37)	<0.001 (<0.001)	0.037 (0.139)	0.001 (<0.001)	<0.001 (<0.001)
BMI, mean (SD)	30.7 (7.3)	29.1 (6.4)	26.1 (4.5)	<0.001 (<0.001)	0.004 (0.003)	<0.001 (<0.001)	<0.001 (<0.001)
BMI Categories:							
Healthy BMI % (n)	21.9 (55)	29.2 (71)	45.7 (117)	<0.001	0.079	<0.001	<0.001
Overweight % (n)	30.3 (76)	32.1 (78)	38.3 (98)				
Obese BMI % (n)	47.8 (120)	38.7 (94)	16.0 (41)				
Percent body fat %, mean (SD)	35.0 (10.7)	32.2 (9.4)	28.7 (9.0)	<0.001 (<0.001)	0.001 (<0.001)	<0.001 (<0.001)	<0.001 (<0.001)
Percent body fat categories:							
Healthy body fat % (n)	20.4 (50)	30.5 (73)	41.0 (105)	<0.001	0.066	<0.001	<0.001

Overweight body fat % (n)	25.7 (63)	23.4 (56)	31.6 (81)				
Obese body fat % (n)	51.4 (126)	44.8 (107)	25.0 (64)				
Fat Free Mass, kg, mean (SD)	55.2 (11.2)	55.8 (12.3)	53.8 (10.5)	0.114 (<0.001)	0.534 (0.285)	0.043 (0.001)	0.159 (0.016)
Waist:Hip Ratio, mean (SD)	0.91 (0.08)	0.90 (0.10)	0.89 (0.08)	0.012 (<0.001)	0.034 (0.005)	0.479 (0.351)	0.004 (<0.001)
Glucose, mmol/L, mean (SD)	5.7 (1.7)	5.4 (0.9)	5.3 (0.5)	<0.001 (<0.001)	0.003 (0.002)	0.203 (0.186)	<0.001 (<0.001)
HBA1c, %, mean (SD)	6.3 (1.2)	5.4 (0.7)	5.2 (0.4)	<0.001 (<0.001)	<0.001 (<0.001)	0.002 (0.001)	<0.001 (<0.001)
Insulin, pmol/L, mean (SD)	65.6 (56.9)	52.7 (54.5)	42.7 (34.4)	<0.001 (<0.001)	0.005 (0.005)	0.025 (0.024)	<0.001 (<0.001)
Smoking:							
Current % (n)	42.8 (108)	30.5 (74)	15.2 (39)	<0.001	<0.001	<0.001	<0.001
Ex-smoker % (n)	38.5 (97)	33.3 (81)	29.3 (75)				
Never smoked % (n)	19.0 (48)	36.2 (88)	55.5 (142)				
Cigarette pack years, mean (SD)	5737 (4910)	5469 (5429)	4308 (5760)	0.045 (0.058)	0.615 (0.588)	0.060 (0.042)	0.015 (0.009)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Alcohol Drinkers, % (n)	81.3 (205)	92.2 (224)	91.4 (234)	<0.001 (0.002)	0.001 0.003	0.753 0.808	0.001 0.005
Physically Active % (n)	68.3 (172)	70.8 (172)	64.8 (166)	0.362 (0.316)	0.157 (0.380)	0.542 (0.132)	0.416 (0.380)

Continuous variables expressed as means (SD). Adj *P* = *P* value adjusted for age and gender.

Ranges for BMI were healthy range, BMI ≥ 18.5 <25.0kg/m²; overweight, BMI 25.0 – 29.9 kg/m²; obese ≥ 30.0 kg/m². Healthy, overweight and obese body fat ranges calculated using Tanita Body Composition Analyser, TBF 310.

Lifestyle risk factors

Rural Māori had the highest rate of current smoking (Table 2). In both Māori cohorts more females were current smokers and more males were ex-smokers; however there was a trend for males to have a higher calculated number of pack years than females across all three cohorts. Current smokers were of similar mean age (42.0 ± 10.5 vs 41.0 ± 10.7 vs 40.7 ± 12.5 years, $P=0.754$).

Alcohol drinking was significantly less common in rural Māori than either urban Māori or non-Māori ($P=0.002$), but the two urban communities were similar in their proportions of alcohol drinkers. The mean age of current drinkers tended to be similar in all three cohorts (rural Māori 44.5 ± 11.4 vs urban Māori 42.4 ± 11.2 years; non-Māori 43.1 ± 11.4 years, $P=0.153$). Recommended sessional drinking limits (no more than 6 standard drinks per session) were reported to be exceeded daily by 2% rural Māori, 3% urban Māori, 1% non-Māori, weekly by 26% rural Māori, 21% urban Māori and 11% urban non-Māori, monthly or less by 55% rural Māori, 44% urban Māori and 48% non-Māori drinkers.

Physical activity within recommended guidelines was reported by similar proportions of rural Māori, urban Māori and non-Māori (Table 1). Physical activity was not independently associated with any other cardiovascular risk factors.

Almost all participants were registered with a General Practitioner (GP) at the time of screening. Similar proportions of each cohort had visited their doctor within the last 6 months (69% vs 61% vs 66%) or had visited their doctor within the last 12 months (85% vs 74% vs 79%).

Levels of previously undiagnosed hypertension and dyslipidaemia

At screening, approximately 20% of each community were found to have blood pressures above the recommended range (Undiagnosed Hypertension, Table 3). Overall, the combined rates of diagnosed and undiagnosed hypertension across the three cohorts were not significantly different between the two Māori cohorts when adjusted for age, but higher in urban Māori than in non-Māori.

For rural Māori, key risk factors in a logistic regression model for predicting hypertension were gender x age (OR=1.243 (1.061 - 1.155), $P<0.0001$), BMI (OR=1.107 (1.033 - 1.135), $P<0.001$), current smoker (OR=0.461 (0.213 - 0.995), $P=0.049$) and family history of hypertension (OR=2.042 (1.178 - 3.540), $P=0.011$). For urban Māori, key risk factors for predicting hypertension were gender x age (OR=1.257 (1.106 - 1.430), $P<0.0001$), an obese % body fat, (OR=4.394 (2.168 - 8.907), $P<0.0001$) and family history of hypertension (OR=1.972 (1.074 - 3.619), $P=0.029$). Among non-Māori, the interaction of gender x fasting triglyceride levels (OR=1.886 (1.366 - 2.603), $P<0.0001$) and age (OR=1.512 (1.161-1.968), $P=0.002$) were the risk factors significantly associated with having hypertension.

New diagnoses of dyslipidaemia made at screening (Undiagnosed Dyslipidaemia, Table 3) were significantly more common in urban Māori after accounting for age than in either rural Māori or non-Māori. Overall, when diagnosed and undiagnosed dyslipidaemia were combined, over half of each Māori cohort and 45% of non-Māori were dyslipidaemic.

For rural Māori, the only independent risk factor identified in a logistic regression model for predicting dyslipidaemia was waist circumference (OR=1.027 (1.009 - 1.044), $P=0.003$). In urban Māori, dyslipidaemia was predicted by an interaction of gender and BMI (OR=0.960

1
2
3 (0.94 – 0.98, $P<0.0001$, male being protective) and an inverse effect of first-degree family
4 history of high cholesterol (OR=0.55 (0.32 – 0.96), $P=0.034$). The interaction of gender x
5 BMI was also identified in urban non-Māori; associated with a protective effect in males
6
7 (OR=0.95 (0.93 – 0.97), $P<0.0001$).
8
9
10

11 12 13 14 **5-year CVD risk scores**

15
16 The calculated 5-year CVD risk scores, as published in the New Zealand CVD Risk
17 Guidelines²² and stratified by age range and gender, are shown in Table 4. These scores
18 estimate the likelihood of having a CVD event (myocardial infarction, new angina, ischaemic
19 stroke, transient ischaemic attack (TIA), peripheral vascular disease, congestive heart failure
20 and cardiovascular-related death) within the next 5 years, and are based on an algorithm
21 including age, gender, systolic blood pressure, TC: HDL ratio, current smoker or not, and
22 presence or absence of diabetes. In addition, the Guidelines recommend that scores for certain
23 high-risk population groups, including Māori be moved up one risk category (5% added).
24
25 Therefore, the two Māori cohorts have an additional 5% making direct comparisons with the
26 non-Māori group difficult. Nonetheless, Table 4 shows the expected trend of increasing risk
27 scores across the three cohorts from rural Māori, to urban Māori, to non-Māori in all age and
28 gender categories except in 60-65 year-old males, where urban Māori males have the highest
29 risk.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Prior and New Diagnoses of Cardiovascular Risk Factors in Rural Māori, Urban Māori and Urban Non-Māori

	Rural Māori	Urban Māori	Non-Māori	Overall	(a) vs (b)	(b) vs (c)	(a) vs (c)
	(a)	(b)	(c)	Unadj <i>P</i>	Unadj <i>P</i>	Unadj <i>P</i>	Unadj <i>P</i>
				(Adj <i>P</i>)	(Adj <i>P</i>)	(Adj <i>P</i>)	(Adj <i>P</i>)
Hypertension:							
Prior Diagnosis Hypertension, %	25.0	14.8	10.5	<0.001	0.006	0.157	<0.001
				(0.001)	(0.115)	(0.061)	(<0.001)
Undiagnosed Hypertension, %	22.2	23.5	17.6	0.235	0.744	0.105	0.191
				(0.124)	(0.744)	(0.054)	(0.109)
Total hypertension, %	47.2	38.3	28.1	<0.001	0.045	0.016	<0.001
				(<0.001)	(0.236)	(0.002)	(<0.001)
Dyslipidaemia:							
Prior Diagnosis Dyslipidaemia, %	15.7	7.1	2.8	<0.001	0.004	0.032	<0.001
				(<0.001)	(0.051)	(0.007)	(<0.001)
Undiagnosed Dyslipidaemia, %	42.6	55.0	42.4	0.008	0.005	0.006	0.961
				(0.004)	(0.014)	(0.002)	(0.570)
Total Dyslipidaemia, %	58.2	62.2	45.6	0.001	0.373	<0.001	0.005
				(<0.001)	(0.261)	(<0.001)	(<0.001)

Undiagnosed = no prior diagnoses or receiving treatment; Total diagnoses = Potential + Previous diagnosis; Adj *P*-value = adjusted for age

Table 4: Mean 5-year CVD risk scores* by age and gender in the rural Maori, urban Maori and urban non-Maori cohorts.

Age Range (Years)	Rural Māori CVD Risk Score (n)			Urban Māori CVD Risk Score (n)			Urban non- Māori CVD Risk Score (n)		
	Males N=102	Females N=150	All N=252	Males N=110	Females N=133	All N=243	Males N=125	Females N=131	All N=256
20 -- 29	5.4 % (10)	5.1 % (20)	5.2 % (30)	5.1 % (15)	5.0 % (22)	5.1 % (37)	1.3 % (16)	0.5 % (19)	0.9 % (35)
30 -- 39	6.6 % (23)	6.1 % (33)	6.3 % (56)	6.7 % (32)	5.3 % (34)	6.0 % (66)	3.9 % (32)	2.6 % (38)	3.2 % (70)
40 -- 49	9.9 % (22)	8.0 % (41)	8.6 % (63)	9.0 % (33)	7.2 % (42)	7.9 % (75)	6.0 % (36)	4.5 % (37)	5.2 % (73)
50 -- 59	15.0 % (32)	10.8 % (43)	12.6 % (75)	14.4 % (21)	10.8 % (22)	12.6 % (43)	10.9 % (28)	6.4 % (24)	8.8 % (52)
60 -- 65	14.6 % (15)	16.7 % (13)	15.6 % (28)	22.2 % (9)	14.5 % (13)	17.6 % (22)	16.1 % (13)	10.1 % (13)	13.1% (26)

*Calculated by BestPractice© software according to the New Zealand CVD Risk Guidelines²² – note that all those of Māori ethnicity have score adjusted upwards by 5% in the NZ CVD Risk Scores.

DISCUSSION

Cardiovascular disease is the major factor contributing to the ethnic disparities of life expectancy between Māori and non-Māori in NZ, and yet how key risk factors contributing to this discrepancy vary across different localities has not previously been described. To our knowledge, this is the first study to compare current levels of CVD and associated risk factors between two regionally distinct Māori communities; rural Māori residing in an area remote from health services and urban Māori in a city well served with secondary and tertiary health services, as well as non-Māori residing in the same locality. The salient finding was a gradient of cardiovascular risk with the highest burden of CVD risk in rural Māori, particularly obesity, smoking, hypertension, dyslipidaemia, DM2 and hyperuricaemia. Increased measures of body mass were key risk factors associated with the elevated fasting insulin and glucose levels, diagnosed hypertension and dyslipidaemia in both Māori cohorts, but particularly in rural Māori. However, we also observed that undiagnosed hypertension and dyslipidaemia were common across all three New Zealand population groups, despite the establishment of nationwide CVD screening guidelines.

Findings in relation to national statistics

The 2006/07 New Zealand Health Survey documented self-reported health information across the New Zealand population, and included analysis by ethnicity but not by locality²⁴.

National prevalence rates were comparable to levels of CVD risk factors we observed in urban Māori but would substantially underestimate CVD risk in rural Māori. For example, 13.6% of the national population reported having medicated high blood pressure²⁴, similar to the 14.9% in our urban Māori but less than the 25% in our rural Māori participants.

Nationwide, one in twelve adults (8.4%) had medicated high cholesterol, comparable to the 7.1% in urban Māori in the current study but less than the 15.7% in rural Māori. The national

1
2
3 prevalence of diagnosed DM2 was 5% in the general population²⁴ and 5.8% in Māori (age-
4
5 adjusted)²⁴. Rural Māori in the current study had double those rates (10.7%) compared to
6
7 only 3.7% in urban Māori and 2.4% in non-Māori. National rates of smoking remain higher
8
9 in Māori (42.2%) compared to the general New Zealand population (19.9%)²⁴. In the current
10
11 study, 42.8% of rural Māori and 30.5% of urban Māori were smokers compared to 15% of
12
13 urban non-Māori. In the New Zealand Health Survey only 50.5% of adults report being
14
15 physically active²⁴. In our data, the multivariate model predicting hypertension appears to
16
17 indicate that smoking exerts a protective effect on hypertension in rural Māori. This apparent
18
19 smoker's paradox, where current smokers have less hypertension or better CVD outcomes
20
21 than former or never smokers, has been previously reported in the literature^{25,26}. It has been
22
23 suggested that smoking protects against hypertension only in overweight and obese, but not in
24
25 normal weight individuals,²⁵ which may explain why it is more evident in the rural cohort. In
26
27 the current study, around 70% of each cohort reported being physically active, consistent with
28
29 national data reporting that Māori are at least as physically active as any other ethnic group in
30
31 New Zealand²⁴. It is apparent that the large BMIs and metabolic risk factors observed among
32
33 the Māori participants were not associated with a less active lifestyle.
34
35
36
37
38
39

40 Plasma urate levels, an independent predictor of cardiovascular disease²³, were above
41
42 reference ranges in 25% of rural Māori and 10% of urban Māori. The national prevalence of
43
44 gout is 1.3%, substantially lower than in the current study, with 6% of rural Māori and 4% of
45
46 urban Māori having been diagnosed by a doctor with gout. It has been known for some
47
48 decades that gout is a common problem in Māori and Pacific Islanders²⁷⁻²⁹ as a result of a
49
50 difference in renal urate handling³⁰. Very recently, two genetic variants have been shown to
51
52 have genome-wide significant association with gout³¹. One of these, a variant form of the
53
54 renal urate transporter gene, SLC2A9, has been shown to be significantly associated with gout
55
56
57
58
59
60

1
2
3 in Māori and Pacific Island patients³². Serum urate levels may be an important underlying
4
5 risk factor in Māori and Pacific people.
6
7

8
9
10 The estimated 5-year CVD risk scores within each age and gender category showed a trend
11
12 for increasing risk from urban non-Māori to urban Māori and then to rural Māori (except for
13
14 males aged 60-64 years). However, these differences were more subtle than might have been
15
16 expected, considering the differences among the cohorts of each composite risk factor used in
17
18 the CVD risk score calculation. For example, rural Māori had higher levels of ~~obesity,~~
19
20 smoking, hypertension, and DM2 than either urban Māori or non-Māori and yet the maximum
21
22 differences between the cohorts in risk scores were less than the 5% adjustment added to
23
24 those of Māori ethnicity. This suggests that overlapping risk factors (eg being Māori, having
25
26 long term DM2 and having family history of CVD, in which case 5% adjustment is applied
27
28 only once) may dampen the CVD risk score, possibly underestimating extremes of risk
29
30 observed in some individuals. Moreover, obesity, a salient risk factor that differed across the
31
32 cohorts, is not included in the CVD risk score algorithm. Also, small differences in the age
33
34 distributions between the rural Māori cohort and the other two groups might limit
35
36 comparisons of CVD risk scores since the scores may not predict well for younger
37
38 individuals. The performance of the NZ risk assessment equation in predicting five-year CVD
39
40 events, particularly for Māori, is currently undergoing scrutiny and reconsideration in the
41
42 published literature.³³⁻³⁵ We propose the individual risk profiles may be more informative
43
44 when deciding clinical management for a specific patient.
45
46
47
48
49
50

51 **Findings in relation to other regional studies**

52
53 The current community cohort design is comparable with an Auckland study based on cross-
54
55 sectional sampling, the Diabetes Heart and Health Survey 2002/2003⁵⁻⁷. In that study, 37% of
56
57
58
59
60

1
2
3 Māori and 22% of others had raised blood pressure, with 7% of Māori and 2% of others
4
5 having previously undetected high blood pressure; more diagnosed but less undiagnosed
6
7 hypertension than in the current study. Mean total: HDL cholesterol ratios were 4.32 in Māori
8
9 and 4.04 in others, comparable to our urban Māori and non-Māori cohorts. In addition,
10
11 approximately 94% of participants had total cholesterol levels above 4.0 mmol/L, similar to
12
13 the current study (90.7% across all three cohorts); an alarming proportion of each cohort with
14
15 lipid profiles above recommended ranges. These findings suggest that elevated cholesterol is
16
17 a key risk factor that is widespread in the New Zealand population and could be more
18
19 intensively screened and managed throughout primary care. The Auckland prevalence of
20
21 DM2 was 12% in Māori ⁹, similar rates to the rural Māori, and 3.9% in Europeans similar to
22
23 both our urban cohorts. Metabolic syndrome was identified in 32% Auckland Māori and 16%
24
25 of others ⁷. This was less than in our rural Māori sample (35.9%) but similar to our urban
26
27 cohorts (27.1% and 14.5%). In combination, these data suggest that levels of several risk
28
29 factors in rural Wairoa Māori exceed those among Māori living in Auckland, especially
30
31 smoking, undiagnosed hypertension and metabolic syndrome. This contrasts with prior
32
33 studies from Thailand ³⁶ and Peru ³⁷, that reported higher metabolic and CVD risk factors in
34
35 urban dwellers than rural residents. However, in Australia metabolic risk was higher in rural
36
37 patients with DM2 ³⁸, as in the current study.
38
39
40
41
42
43
44

45
46 The current findings reflect a previous study of metabolic and cardiovascular health in a rural
47
48 Māori community of the Tuhoe tribe performed fifty years ago ^{12, 39}. Prior et al screened 212
49
50 Tuhoe adults living in the isolated Ruatahuna Valley in the Urewera region ^{12, 39}. The study
51
52 highlighted high rates of coronary heart disease, obesity, high cholesterol, hyperuricaemia,
53
54 clinical gout and diabetes. It is difficult to compare the specific data with the current study, as
55
56 many of the indices measured are no longer in use, such as “relative weight” and the use of
57
58
59
60

1
2
3 skin fold measurements to assess body fat. There was a 5% prevalence of rheumatic heart
4
5 disease; considerably higher than the 2% of rural Māori in the current study. Rates of smoking
6
7 were 59% among men and 70% among women, also substantially higher than we observed in
8
9 the rural Wairoa cohort. However, mean blood pressure and rates of DM2 were similar to
10
11 current Wairoa residents. From those findings, alongside the current study, it would appear
12
13 that health issues besetting rural Māori have improved only a little over the past half century.
14
15

16 17 18 **Strengths and limitations of the study** 19

20
21 This study was able to determine current levels of both diagnosed and undiagnosed risk
22
23 factors within these communities by conducting CVD screening clinics in sectors of the
24
25 community that are often hard-to-reach. Prior reports based on areal surveys (usually reliant
26
27 on self-reported diagnoses) or clinical databases may substantially underestimate disease rates
28
29 and risk factors in indigenous population groups who may not have equivalent access to
30
31 health care or CVD screening. The findings of this study are limited by the relatively small
32
33 cohort sizes, the study design being constrained by the costs of the in-depth CVD screening.
34
35 Also, the lack of a rural non-Māori comparator cohort is a limiting factor, resulting from the
36
37 difficulty in achieving a matched non-Māori sample because of the small number of non-
38
39 Māori in Wairoa and differing demographics between Māori and non-Māori in the District. In
40
41 addition, there were slight differences in age distributions between the rural Māori sample and
42
43 the other two cohorts. While most age-dependent measures were able to be age-adjusted, the
44
45 algorithm used to calculate the CVD risk scores includes age as a risk factor, and hence could
46
47 not be age adjusted. The authors recognise that use of two blood pressure measurements in a
48
49 clinic setting is not a definitive diagnosis of hypertension.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In conclusion, this study reports that compared to either urban Māori or non-Māori, there is a
4
5 greater burden of CVD risk factors, particularly obesity, hypertension, dyslipidaemia, DM2,
6
7 hyperuricaemia and smoking in rural Māori, who have remained largely unstudied for the past
8
9 half-century. Moreover, the findings demonstrate that CVD risk profiles ascertained in
10
11 national health surveys or in New Zealand's largest metropolitan population do not
12
13 necessarily reflect other localities; Christchurch Māori appear to have lower risk than
14
15 Auckland Māori, while Māori living in rural Wairoa have substantially higher risk. Despite
16
17 two-thirds of all three cohorts reporting visiting their primary care physicians in the past six to
18
19 twelve months, the study identified similarly high levels of undiagnosed hypertension and
20
21 elevated cholesterol in each of the population samples. Rural Māori participants reported
22
23 similar attendance of participants with their GPs, indicating good engagement with primary
24
25 care and suggesting that higher rates of some risk factors among the rural contingent were not
26
27 necessarily associated with barriers to accessing primary care. However, it seems likely public
28
29 health initiatives to reduce rates of smoking among Māori, along with enhanced
30
31 implementation of CVD screening in primary care and more support for rural general
32
33 practices to provide intensive clinical management of hypertension, dyslipidaemia and
34
35 hyperuricaemia would help reduce the CVD health disparities in the New Zealand indigenous
36
37 population.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Ajwani S, Blakely T, Robson B, Tobias M, Bonne M. *Decades Of Disparity: Ethnic Mortality Trends in New Zealand 1980 -1999*. Public Health Intelligence 2003; Occasional Bulletin Number 16. Wellington: Ministry of Health and University of Otago; 2003.
2. Bramley D, Riddell T, Crengle S, Curtis E, Harwood M, Nehua D, Reid P. A call to action on Maori cardiovascular health. *NZMJ*. 2004;**117**(1197) URL: <http://www.nzma.org.nz/journal/117-1197/957/>
3. Ministry of Social Development. *Health 2010 - The Social Report*. Download from the New Zealand Ministry of Social Development website: <http://socialreport.msd.govt.nz/documents/health-social-report-2010.pdf>
4. Riddell T, Jackson R, Wells S, Broad J, Bannink L. Assessing Maori/non-Maori differences in cardiovascular disease risk and risk management in routine primary care practice using web-based clinical decision support: (PREDICT CVD-2). *NZMJ*. 2007;**120**(1250) URL: <http://www.nzma.org.nz/journal/120-1250/2445/>
5. Gentles D, Metcalf P, Dyal L, Scragg R, Black P, Schaaf D, Sundborn G, Jackson R. Blood pressure prevalences and levels for a multicultural population in Auckland, New Zealand: Results from the Diabetes, Heart And Health Survey 2002/2003. *NZMJ*. 2006;**119**(1245) URL: <http://www.nzma.org.nz/journal/119-1245/2318/>
6. Gentles D, Metcalf P, Dyal L, Scragg R, Sundborn G, Schaaf D, Black P, Jackson R. Serum lipid levels for a multicultural population in Auckland, New Zealand: Results from the diabetes, heart and health survey (dhah) 2002-2003. *NZMJ*. 2007;**120**(1265) URL: <http://www.nzma.org.nz/journal/120-1265/2800/>
7. Gentles D, Metcalf P, Dyal L, Sundborn G, Schaaf D, Black P, Scragg R, Jackson R. Metabolic syndrome prevalence in a multicultural population in Auckland, New

- 1
2
3 Zealand. *NZMJ*. 2007;**120**(1248) URL: [http://www.nzma.org.nz/journal/120-](http://www.nzma.org.nz/journal/120-1248/2387/)
4
5 1248/2387/
6
7
8 8. Metcalf P, Scragg R, Schaaf D, Dyal L, Black P, Jackson R. Trends in major
9
10 cardiovascular risk factors in Auckland, New Zealand: 1982 to 2002-2003. *NZMJ*.
11
12 2006;**119**(1245) URL: <http://www.nzma.org.nz/journal/119-1245/2308/>
13
14 9. Sundborn G, Metcalf P, Scragg R, Schaaf D, Dyal L, Gentles D, Black P, Jackson R.
15
16 Ethnic differences in the prevalence of new and known diabetes mellitus, impaired
17
18 glucose tolerance, and impaired fasting glucose. Diabetes, Heart and Health Survey
19
20 (DHAH) 2002-2003, Auckland New Zealand. *NZMJ*. 2007;**120**(1257) URL:
21
22 <http://www.nzmj.com/journal/120-1257/2607>
23
24
25 10. Statistics New Zealand. 2006 Census Quickstats about Auckland Region. 2006
26
27 (Accessed 29 April 2011) URL:
28
29 [http://www.stats.govt.nz/Census/2006CensusHomePage/QuickStats/AboutAPlace/Sna](http://www.stats.govt.nz/Census/2006CensusHomePage/QuickStats/AboutAPlace/SnapShot.aspx?id=1000002&type=region&ParentID=)
30
31 [pShot.aspx?id=1000002&type=region&ParentID=](http://www.stats.govt.nz/Census/2006CensusHomePage/QuickStats/AboutAPlace/SnapShot.aspx?id=1000002&type=region&ParentID=)
32
33
34 11. National Health Committee. *Rural Health: Challenges of Distance; Opportunities For*
35
36 *Innovation*. Wellington: Ministry of Health; 2010.
37
38
39 12. Prior I. A health survey in a rural Maori community, with particular emphasis on the
40
41 cardiovascular, nutritional and metabolic findings. *NZMJ*. 1962;61:333-348
42
43 13. Faatoese A, Pitama S, Gillies T, Robertson P, Huria T, Tikao-Mason K, Doughty R,
44
45 Whalley G, Richards A, Troughton R, Sheerin I, Wells J, Cameron V. Community
46
47 screening for cardiovascular risk factors and levels of treatment in a rural Māori
48
49 cohort. *Aust N Z J Public Health*. 2011;35:517-523
50
51
52 14. Statistics New Zealand. Defining urban and rural New Zealand. 2006 (Accessed 27
53
54 March 2012) URL:
55
56
57
58
59
60

- 1
2
3 [http://www.stats.govt.nz/browse_for_stats/people_and_communities/geographic-](http://www.stats.govt.nz/browse_for_stats/people_and_communities/geographic-areas/urban-rural-profile/defining-urban-rural-nz.aspx)
4 [areas/urban-rural-profile/defining-urban-rural-nz.aspx](http://www.stats.govt.nz/browse_for_stats/people_and_communities/geographic-areas/urban-rural-profile/defining-urban-rural-nz.aspx)
5
6
7
8 15. Statistics New Zealand. 2006 Census quickstats about Wairoa district. 2006 (Accessed
9 27 March 2012) URL:
10 [http://www.stats.govt.nz/Census/2006CensusHomePage/QuickStats/AboutAPlace/Sna](http://www.stats.govt.nz/Census/2006CensusHomePage/QuickStats/AboutAPlace/SnapShot.aspx?id=2000029&type=ta&ParentID=1000006)
11 [pShot.aspx?id=2000029&type=ta&ParentID=1000006](http://www.stats.govt.nz/Census/2006CensusHomePage/QuickStats/AboutAPlace/SnapShot.aspx?id=2000029&type=ta&ParentID=1000006)
12
13
14
15
16 16. Statistics New Zealand. 2006 Census quickstats about Christchurch. 2006 (Accessed
17 27 March 2012) URL:
18 [http://www.stats.govt.nz/Census/2006CensusHomePage/QuickStats/AboutAPlace/Sna](http://www.stats.govt.nz/Census/2006CensusHomePage/QuickStats/AboutAPlace/SnapShot.aspx?id=2000060&type=ta&ParentID=1000013)
19 [pShot.aspx?id=2000060&type=ta&ParentID=1000013](http://www.stats.govt.nz/Census/2006CensusHomePage/QuickStats/AboutAPlace/SnapShot.aspx?id=2000060&type=ta&ParentID=1000013)
20
21
22
23
24
25 17. Pitama S, Wells J, Faatoese A, Tikao-Mason K, Robertson P, Huria T, Gillies M,
26 Doughty R, Whalley G, Troughton R, Sheerin I, Richards M, Cameron V. A
27 community cohort study of heart disease in New Zealand with two indigenous samples
28 (rural and urban) and an urban non-indigenous sample: Design, methods, response
29 rates and referral after baseline screening. *Aust NZ J Pub Health*. 2011;35:249-255
30
31
32
33
34
35
36 18. Elections New Zealand. Enrolment statistics. 2012(Accessed 27 March 2012) URL:
37 http://www.elections.org.nz/ages/electorate_all.html
38
39
40
41 19. Callister P, Didham R, Potter D, Blakely T. Measuring ethnicity in New Zealand:
42 Developing tools for health outcomes analysis. *Ethn Health*. 2007;12:299-320
43
44
45 20. Thomas D. Assessing ethnicity in New Zealand health research. *NZMJ*. 2001;114:86-
46 88
47
48
49 21. Smith L. *Decolonizing Methodologies: Research and Indigenous Peoples*. London:
50 Zed Books; 1999.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22. New Zealand Guidelines Group. *New Zealand Cardiovascular Guidelines Handbook: A Summary Resource for Primary Care Practitioners*. Wellington: Ministry of Health; 2009.
 23. Ioachimescu A, Brrennan D, Hoar B, Hazen S, Hoogwerf B. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease. *Arthritis Rheum*. 2008;58:623-630
 24. Ministry of Health. *A portrait of Health. Key results of the 2006/2007 New Zealand Health Survey*. Wellington: Ministry of Health; 2008.
 25. John U, Meyer C, Hanke M, Volzke H, Schumann A. Smoking status, obesity and hypertension in a general population sample: A cross-sectional study. *Q J Med*. 2006;99:407-415
 26. Weisz G, Cox D, Garcia E, Tchong J, Griffin J, Guagliumi G, Stuckey T, Rutherford B, Mehran R, Aymong E, Lansky A, Grines C, Stone G. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—the smoker’s paradox revisited. *Am Heart J*. 2005;150:358-364
 27. Brauer G, Prior I. A prospective study of gout in New Zealand Maoris. *Ann Rheum Dis*. 1978;37:466-472
 28. Klemp P, Stansfield S, Castle B, Robertson M. Gout is on the increase in New Zealand. *Ann Rheum Dis*. 1997;56:22-30
 29. Stamp L, Gow P, Sharples K, Raill B. The optimal use of allopurinol: An audit of allopurinol use in South Auckland. *Aust N Z J Med*. 2000;30:567-572
 30. Simmonds H, McBride M, Hatfield P, Garaham R, McCaskey J, Jackson M. Polynesian women are also at risk for hyperuricaemia and gout because of a genetic defect in renal urate handling. *Br J Rheumatol*. 1994;33:932-937

- 1
2
3 31. Yang Q, Köttgen A, Dehghan A, Smith A, Glazer N, Chen M, Chasman D, Aspelund
4 T, Eiriksdottir G, Harris T, Launer L, Nalls M, Hernandez D, Arking D, Boerwinkle
5 E, Grove M, Li M, Linda Kao W, Chonchol M, Haritunians T, Li G, Lumley T, Psaty
6 B, Shlipak M, Hwang S, Larson M, O'Donnell C, Upadhyay A, van Duijn C, Hofman
7 A, Rivadeneira F, Stricker B, Uitterlinden A, Paré G, Parker A, Ridker P, Siscovick D,
8 Gudnason V, Witteman J, Fox C, Coresh J. Multiple genetic loci influence serum urate
9 levels and their relationship with gout and cardiovascular disease risk factors. *Circ*
10 *Cardiovasc Genet*. 2010;3:523-530
11
12 32. Hollis-Moffatt J, Xu X, Dalbeth N, Merriman M, Topless R, Waddell C, Gow P,
13 Harrison A, Highton J, Jones P, Stamp L, Merriman T. Role of the urate transporter
14 SLC2A9 gene in susceptibility to gout in New Zealand Māori, Pacific Island, and
15 Caucasian case-control sample sets. *Arthritis Rheum*. 2009;60:3485-3492
16
17 33. Elley C, Robinson E, Kenealy T, Bramley D, Drury P. Derivation and validation of a
18 new cardiovascular risk score for people with type 2 diabetes. *Diabetes Care*.
19 2010;33:1347-1352
20
21 34. Metcalf P, Wells S, Scragg R, Jackson R. Comparison of three different methods of
22 assessing cardiovascular disease risk in new zealanders with type 2 diabetes mellitus.
23 *NZMJ*. 2008;121:49-57
24
25 35. Riddell T, Wells S, Jackson R, Lee A-W, Crengle S, Bramley D, Ameratunga S,
26 Pylypchuk R, Boaroad J, Marshall R, Kerr A. Performance of framingham
27 cardiovascular risk scores by ethnic groups in new zealand: Predict cvd-10. *NZMJ*.
28 2010;123:50-60
29
30 36. The InterASIA Collaborative Group. Cardiovascular risk factor levels in urban and
31 rural Thailand – the international collaborative study of cardiovascular disease in Asia
32 (interASIA). *Eur J Cardiovasc Prev Rehabil*. 2003;10:249-257
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 37. Masterson Creber R, Smeeth L, Gilman R, Miranda J. Physical activity and
4 cardiovascular risk factors among rural and urban groups and rural-to-urban migrants
5 in Peru: A cross-sectional study. *Rev Panam Salud Publica*. 2010;28:1-8
6
7
8
9
10 38. Wan Q, Harris M, Powell-Davies G, Jayasinghe U, Flack J, Georgiou A, Burns J,
11 Penn D. Cardiovascular risk levels in general practice patients with type 2 diabetes in
12 rural and urban areas. *Aust. J Rural Health*. 2007;15:327-333
13
14
15
16 39. Prior I, Rose B, Davidson F. Metabolic maladies in New Zealand Maoris. *BMJ*.
17 1964;1:1065-1069
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1 and 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5 and 6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6 and 7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7 to 9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8 and 9
Bias	9	Describe any efforts to address potential sources of bias	7 and 9 (decision support software used)
Study size	10	Explain how the study size was arrived at	6 (previous Methods publication cited)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	9

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6 (previous Methods publication cited)
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	9
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9, 11-21
		(b) Report category boundaries when continuous variables were categorized	17
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	23
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	27
Generalisability	21	Discuss the generalisability (external validity) of the study results	23-26
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Uploaded to website

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only